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ABSTRACT 
Targeting apoptosis pathways is one of the key strategies for cancer treatment. Tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) induces apoptosis in a 
variety of tumor cells but not in non-malignant cells. Therefore, TRAIL is a promising 
anti-cancer agent. However, approximately 50 % of cancers are resistant to TRAIL, 
including the human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell 
leukemia (ATL). So far various treatment strategies are offered to ATL patients, but 
the mortality of ATL remains very high due to apoptosis resistance. 
Our group has previously shown that Wogonin, derived from the Traditional Chinese 
Medicine (TCM) plant Huang-Qin (Scutellaria baicalensis Georgi), can sensitize 
TRAIL-mediated apoptosis in primary AML (acute myeloid leukemia) cells. 
Importantly, Wogonin does not affect the viability of peripheral blood T cells derived 
from healthy donors. However, the mechanisms of Wogonin-mediated sensitization of 
TRAIL-induced apoptosis are still not known.  
In this study, HTLV-1-associated ATL cell lines SP, MT-2 and MT-4 were used to 
investigate resensitization resistant tumor cells to TRAIL-induced apoptosis. We 
found that Wogonin sensitized TRAIL-induced apoptosis in HTLV-1-associated ATL 
cells by down-regulation of caspase-8 inhibitory protein (FLICE)-like inhibitory 
protein (c-FLIP) expression at the transcriptional level. In addition, Wogonin 
enhanced the expression of TRAIL receptor 2 (TRAIL-R2) via up-regulation of p53. 
Increased p53 expression was due to inhibition of p53 negative regulator MDM2 at 
the transcriptional level. We also demonstrated that structurally related natural 
flavones, e.g. Apigenin and Chrysin, inhibited c-FILP at the transcriptional level and 
increased TRAIL-R2 expression via up-regulation of p53 through suppression of p53 
negative regulator MDM2 in HTLV-1-associated ATL cells. Our study raises the 
possibility to develop Wogonin, Apigenin and Chrysin as TRAIL adjuvants for 
treatment of ATL and other types of tumors.  
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ZUSAMMENFASSUNG 
Einer der Hauptstrategien zur Behandlung von Krebs ist das Auslösen des 
programmierten Zelltods (Apoptose) in Tumorzellen. Das Protein TRAIL (tumor 
necrosis factor-related apoptosis-inducing ligand) kann Apoptose in einer Vielzahl 
von Tumorzelllinien, aber nicht in normalen Körperzellen, induzieren. Allerdings 
weisen etwa die Hälfte aller Tumore eine Resistenz gegenüber TRAIL auf, unter 
anderem auch die mit dem humanen T-lymphotropen Virus 1 (HTLV-1) assoziierte 
adulte T-Zellleukämie (ATL). Aufgrund der Apoptoseresistenz dieser Leukämieart 
sind alle derzeit verfügbaren Behandlungsstrategien mit geringen Erfolgsaussichten 
verbunden und die Sterblichkeitsrate bei ATL Patienten ist sehr hoch.  
In unserer Arbeitsgruppe konnte gezeigt werden, dass Wogonin, ein Bestandteil der 
traditionellen chinesischen Heilpflanze Huang-Qin (Scutellaria baicalensis Georgi), 
primäre AML (akute myeloide Leukämie) Zellen gegenüber TRAIL-induzierter 
Apoptose sensitivieren kann. Die Viablitiät nicht maligner peripherer T-Zellen wird 
durch Wogonin hingegen nicht beeinflusst. Die molekularen Mechanismen, durch 
welche Wogonin resistente Tumorzellen gegenüber TRAIL sensitiviert, sind jedoch 
noch weitgehend unbekannt. 
In dieser Studie wurden die HTLV-1-infizierten ATL Zelllinien SP, MT-2 und MT-4 
als Modellsystem benutzt, um die Sensitivierung resistenter Tumorzellen gegenüber 
der TRAIL-induzierten Apoptose zu untersuchen. Wir konnten zeigen, dass Wogonin 
HTLV-1-infizierte ATL Zelllinien gegenüber TRAIL sensitiviert, indem die 
Expression des Proteins c-FLIP (caspase-8 (FLICE)-like inhibitory protein) auf 
transkriptioneller Ebene gehemmt wird. 
Darüber hinaus steigerte Wogonin die Expression von TRAIL-Rezeptor 2 (TRAIL-R2) 
auf der Zelloberfläche durch Stabiliseurng von p53. Ursächlich für die beobachtete 
p53 Stabilsierung war die von Wogonin vermittelte transkriptionelle Hemmung  von 
MDM2, einem Negativregulator von p53. Außerdem konnten wir nachweisen, dass 
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die strukturell ähnlichen Flavone Apigenin und Chrysin ebenfalls c-FLIP Expression 
auf transkriptioneller Ebene inhibierten und die Expression von TRAIL-R2 in 
HTLV-1-infizierten ATL Zellen verstärkten.  
Auf Grundlage dieser Ergebnisse erscheint es vielversprechend, Wogonin, Apigenin 
und Chrysin in Kombination mit TRAIL zur Behandlung von ATL und anderen 
Tumoren einzusetzen.  
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1. INTRODUCTION  
1.1 Apoptosis  
Apoptosis is an essential mechanism for development, establishment and maintenance 
of tissue architecture. Furthermore, apoptosis plays a role in fighting against 
infections in multicellular organisms. It was in 1842 that Carl Vogt first discovered a 
new type of cell death occurring in a programmed fashion (Vogt et al., 1842). Kerr, 
Wyllie and Currie used the term “apoptosis” to describe the processes of programmed 
cell death in 1972 (Kerr et al., 1972). “Apoptosis” is a Greek word describing the 
“dropping off” or “falling off” of petals from flowers or leaves from trees. In 1989, 
two groups discovered CD95 (APO-1/Fas) by the generation of monoclonal 
antibodies which induce apoptosis in various cell lines (Trauth et al., 1989; Yonehara 
et al., 1989). From then on, apoptosis has attracted great attention and research on 
apoptosis has dramatically increased.  
Apoptosis is characterized by morphological and biochemical traits, including 
membrane blebbing, cell shrinkage, nuclear DNA fragmentation and chromatin 
condensation (Wyllie et al., 1980; Steller et al., 1995). The apoptotic form of cell 
death is different from necrosis which occurs in response to a major insult as injury by 
toxins, or ischemia. Necrosis shows cell swelling, the destruction of cellular 
organelles, rupture of the plasma membranes and finally leakage of the cellular 
content into the environment. The main physiological difference between apoptosis 
and necrosis is that necrotic cells can elicit an inflammatory reaction, whereas 
apoptotic cells are cleared in an inconspicuous fashion, mainly by phagocytosis by 
neighboring cells or by specialized macrophage-like cells (Okada et al., 2004; 
Krammer et al., 2007). 
Apoptosis has to be tightly regulated since dysfunction of apoptosis leads to a variety 
of diseases. On the one hand, insufficient apoptosis may lead to cancer (Thompson, 
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1995), certain autoimmune diseases such as Grave’s disease (Feldmann et al., 1992) 
or Hashimoto’s thyroiditis (Stassi and De Maria, 2002). On the other hand, an excess 
of apoptosis has been associated with several other diseases, such as AIDS (acquired 
immune deficiency syndrome) and neurodegerative disorders (Thompson, 1995; Peter 
et al., 1997; Krammer et al., 2007).  
The process of apoptosis relies on activation of cysteine proteases which are called 
caspases (cysteinyl aspartate-specific protease). These caspases are present in the cells 
as inactive pro-forms (zymogens). Following the induction of apoptosis, these 
pro-forms can be cleaved to form active enzymes which then cleave substrates on the 
carboxyl-side of an aspartate residue (Cohen, 1997; Stennicke, 1998). There are two 
kinds of caspases: initiator caspases including caspase-2, caspase-8, caspase-9 and 
caspase-10 and effector caspases including caspase-3, caspase-6 and caspase-7. 
Activation of initiator caspases leads to the proteolytic activation of the effector 
caspases, which results in the cleavage of specific substrates and execution of cell 
death (Kumar and Lavin, 1996). In addition, a caspase-independent apoptotic pathway 
has also been reported which is mediated by AIF (apoptosis inducing factor) (Susin et 
al., 1999; Sevrioukova, 2011). 
Apoptotic signaling events can be divided into two pathways depending on the 
mechanism of initiation. The extrinsic pathway is activated by engagement of 
extracellular death receptors, while the intrinsic pathway depends on the mitochondria 
(Fig. 1.1). 
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Figure 1.1 Apoptosis signaling pathways. Apoptotic signaling events can be divided into two 
pathways: the extrinsic pathway which is activated by engagement of extracellular death receptors 
and the intrinsic pathway which depends on mitochondria. The extrinsic pathway mainly involves 
binding of ligand to its receptor and activation of the initiator caspase-8 at the DISC level, a 
process which can be inhibited by c-FLIP. The intrinsic pathway is activated by various stimuli, 
such as DNA damage, oxidative stress, irradiation or cytotoxic drugs, which lead to release of 
cytochrome c from mitochondria and activation of caspase-9. This pathway is regulated by the 
anti-apoptotic and pro-apoptotic members of the Bcl-2 family. Pro-apoptotic factors are shown in 
red and anti-apoptotic factors in yellow. The extrinsic pathway and the intirnsic pathway are 
linked by Bid which is cleaved by caspase-8 to a truncated form (tBid). tBid translocates to the 
mitochondria to induce the intrinsic apoptosis pathway. For details see text. 
 
1.1.1 The receptor-mediated (extrinsic) apoptosis pathway 
The extrinsic apoptosis pathway is triggered by the binding of ligands to their 
corresponding death receptors on the cell surface (Krammer et al., 2007; Lavrik et al., 
2005; Schulze-Bergkamen et al., 2004). Six ligands have been reported so far: tumor 
necrosis factor-α (TNF-α), CD95 ligand (CD95L), TNF-like factor (TL1A), 
TNF-related apoptosis-inducing ligand (TRAIL), ectodysplasin A (EDA) and nerve 
DISC 
Extrinsic pathway 
Bid tBid
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Caspase-3 
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Apoptosome 
Cytochrome c
Apaf-1 
Procaspase-9
Intrinsic pathway 
Apoptosis stimuli 
Mcl-1
Bad 
Bcl-xl Bcl-2 
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growth factor (NGF). These ligands are type II transmembrane proteins belonging to 
the TNF/NGF superfamily (Smith et al., 1994). Until now eight death receptors and 
three decoy receptors have been reported. Death receptors are tumor necrosis factor 
receptor 1 (TNFR1), CD95, DR3, TNF-related apoptosis-inducing ligand receptor 1 
(TRAIL-R1), TRAIL-R2, DR6, ectodysplasin A receptor (EDAR), nerve growth 
factor receptor (NGFR), and decoy receptors are TRAIL-R3, TRAIL-R4 and 
osteoprotegerin (OPG) (French and Tschopp, 2003; Wajant, 2003; Lavrik et al., 2005; 
Krammer et al., 2007) (Table 1). These death receptors are characterized by a 
cytoplasmic region of about 80 residues termed the death domain (DD), which is 
necessary and sufficient for induction of apoptosis (Itoh et al., 1993; Tartaglia et al., 
1993; Lorenzo and Susin, 2004).  
CD95 (APO-1/FAS), one of the most studied death receptors, was discovered by the 
generation of monoclonal antibodies which induce apoptosis in various cell lines 
(Trauth et al., 1989; Yonehara et al., 1989). It is a type I transmembrane glycoprotein 
with a molecular mass of 45 to 52 kDa (Itoh et al., 1991; Oehm et al., 1992). The 
ligand for CD95, CD95L, is a 40-kDa type II membrane protein which is only present 
on few cell types, such as activated T cells (Suda et al., 1993) or natural killer (NK) 
cells (Oshimi et al., 1996) as well as cells in immune privileged sites, such as the 
testis, the placenta, the anterior chamber of the eye and the brain (Lee et al., 1997; 
Mitsiades et al., 2003).  
The CD95/CD95L system plays a major role in maintaining homeostasis in the 
immune system. In mouse models it has been demonstrated that mice lacking a 
functional CD95/CD95L system show autoimmune syndromes such as accumulation 
of peripheral lymphocytes and massive enlargement of lymph nodes 
(lymphadenopathy) and spleen (splenomegaly) (Takahashi 1994; Watanabe-Fukunaga 
1992). In humans, mutations in the CD95/CD95L system are associated with an 
autoimmune disorder termed ALPS (autoimmune lymphopoliferative syndrome). 
These patients have accumulation of lymphocytes and an increased risk of developing 
 
 
Introduction                
 18
lymphomas (Lenardo, 2003; Krammer et al., 2007). 
In the extrinsic apoptosis pathway, the DISC (death-inducing signaling complex) is 
formed within seconds after receptor engagement (Peter and Krammer, 2003). The 
CD95 DISC consists of oligomerized CD95 receptors, the DD-containing adaptor 
protein FADD (Fas-associated death domain), the two splice variants pro-caspase-8a 
and pro-caspase-8b and the cellular FLICE-inhibitory protein (c-FLIPL/S/R). FADD 
plays a crucial role in DISC formation, because it bridges the receptors and caspases 
by homotypic interactions between the DD and the death effector domains (DEDs). 
The DD of FADD binds to the DD of the receptor, and via its DED, FADD interacts 
with the DEDs of pro-caspase-8 and -10, which leads to the cleavage process and 
activation of pro-caspase-8 and -10 (Griffith et al., 1999; Chinnaiyan et al., 1995; 
Bouillet and O'Reilly, 2009). Activation of caspase-8 is thought to occur in a two-step 
mechanism. The initial cleavage gives raise to the p43/p41 and the p12 subunits. In 
the second step, the active form of caspase-8, a heterotetramer of two small (p10) and 
two large (p18) subunits, is generated (Micheau et al., 2002; Shi, 2002). For execution 
of apoptosis, it is released into the cytosol to initiate further effector caspase 
activation or to activate the intrinsic apoptosis pathway via cleavage of Bid (Sprick et 
al., 2002; Bouillet and O'Reilly, 2009).  
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Table 1. Death receptors, decoy receptors and their ligands.  
Death receptors  Ligands 
Common name 
TNFR1 
 
 
 
CD95 
 
 
TRAMP 
 
 
 
TRAIL-R1 
 
TRAIL-R2 
 
 
 
 
DR6 
EDAR 
NGFR 
Alternative name 
DR1 
p55 
p60 
CD120a 
DR2 
Fas 
APO-1 
DR3 
APO-3 
WSL-1 
LARD 
DR4 
TNFRSF10A 
DR5 
APO-2 
KILLER 
TRICK2 
TNFRSF10B 
TR-7 
 
 
 
TNF-α 
 
 
 
CD95L 
 
 
TL1A 
 
 
 
TRAIL 
 
TRAIL 
 
 
 
？ 
EDA1 
NGF 
Decoy receptors   
TRAIL-R3 
 
 
TRAIL-R4 
OPG 
DcR1 
TRID 
TNFRSF10C 
DcR2 
TNFRSF10D 
TRAIL 
 
 
TRAIL 
TRAIL 
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1.1.2 c-FLIP, an inhibitor of the extrinsic apoptosis pathway 
FLIP (FADD-like interleukin-1β-converting enzyme-like protease-inhibitory protein) 
is a key regulator of death receptor-mediated apoptotic signaling cascades. The gene 
for FLIP was first discovered in viruses including Kaposi's-sarcoma-associated human 
herpesvirus-8 and the tumorigenic human molluscipoxvirus (Thome et al., 1997). 
Viral FLIP inhibits death receptor-induced apoptosis which might delay cytotoxic T 
lymphocyte-mediated eradication of the infected host cells and prolong viral 
replication time (Bertin et al., 1997; Tschopp et al., 1998; Thurau et al., 2009). Later 
mammalian FLIP proteins were also discovered (Goltsev et al., 1997; Han et al., 1997; 
Hu et al., 1997). Viral FLIP (v-FLIP) and mammalian cellular FLIP (c-FLIP) are 
structurally similar and characterized by two DED motifs at their amino-terminus 
(N-terminus). So far, 11 c-FLIP splice variants have been reported but only three are 
expressed at the protein level: the 26 kDa short form c-FLIPS, the 24 kDa form 
c-FLIPR and the 55 kDa long form c-FLIPL (Bagnoli et al., 2010). c-FLIP shares 
extensive amino acid sequence similarity with pro-caspase-8 and pro-caspase-10 at 
the N-terminus. Additionally, c-FLIPL has one pseudo caspase domain at the 
carboxy-terminus (C-terminus) which is catalytically inactive due to the absence of 
critical residues required for protease activity, such as the catalytic cysteine (Cohen, 
1997). c-FLIPS and c-FLIPR have similar structures. c-FLIPS has been reported 
habouring an carboxy-terminal (C-terminal) extension of 20 amino acids which is 
crucial for ubiquitylation and degradation (Chang et al., 2006) (Fig. 1.2). 
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Figure 1.2 Molecular structures of viral and cellular FLIPs. Both v-FLIP and c-FLIPS are 
characterized by two DED motifs at their amino terminus, which is similar to pro-caspase-8 and 
pro-caspase-10. At the carboxy terminus, c-FLIPL has one pseudo caspase domain which is 
catalytically inactive. c-FLIPS and c-FLIPR have similar structures except that c-FLIPS has an 
carboxy-terminal extension of 20 amino acids which is crucial for ubiquitylation and degradation. 
 
c-FLIP expression is positively regulated by the transcription factors NF-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) and NFAT (nuclear factor of 
activated T-cells), and negatively by c-myc and c-Fos (Shirley and Micheau; 2010). 
Beyond that, c-FLIP isoforms are heavily regulated at the post-translational level by 
the E3 ubiquitin ligase Itch via the proteasomal pathway (Fukazawa et al., 2001). 
Specifically, the c-FLIPS protein contains a unique C-terminal extension of 20 amino 
acids which confers its ubiquitination and degradation, and therefore it has a shorter 
half-life compared to c-FLIPL (Poukkula et al., 2005). Generally, c-FLIP isoforms 
have not only short protein but also short mRNA half-life of about 2 hours. c-FLIP 
expression can be easily attenuated by using protein or RNA synthesis inhibitors 
indicating a short half life (Fulda et al., 2000; Hernandez et al., 2001).  
c-FLIP is widely accepted as an anti-apoptotic protein that functions by preventing 
recruitment and processing of pro-caspase-8 within the DISC. It has been reported 
that c-FLIP can bind to FADD via homotypic DED interactions and partially 
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processed c-FLIP (p43) is retained at the DISC through binding to the FADD/death 
receptor complexes which blocks further recruitment of pro-caspase-8 (Goltsev et al., 
1997; Irmler et al., 1997; Krueger et al., 2001; Shirley and Micheau; 2010). c-FILPS 
can form a caspase/c-FLIPS heterocomplex, which blocks cleavage of caspase-8 
within the DISC. Unlike c-FLIPS, upon heterodimer formation, c-FLIPL allows a 
limited cleavage of pro-caspase-8, leading to the generation of p43/41 and p12 
caspase-8 subunits. However, no further caspase-8 processing occurs to form an 
active heterotetramer of caspase-8 (two small p10 subunits and two large p18 subunits) 
due to the lack of proteolytic activity of c-FLIPL. The cleaved products (p43/41 and 
p12) remain bound at the DISC, preventing further transduction of the apoptotic 
signal (Krueger et al., 2001; Micheau et al., 2002; Shirley and Micheau; 2010). 
Furthermore, current studies indicate that the cleavage product of c-FLIPL interacts 
with the IKK (IκB kinase) complex to activate the non-apoptotic NF-κB signaling 
pathway (Neumann et al., 2010; Golks et al., 2006). Alternatively, c-FLIPL processed 
by caspase-8 promotes recruitment of RIP1 (receptor-interacting kinase 1) and 
TRAF2 (tumor necrosis factor receptor-associated factor 2) and induces activation of 
the NF-κB signaling pathway (Dohrman et al., 2005; Kataoka and Tschopp, 2004).  
c-FLIPL has also been reported to have a pro-apoptotic effect (Lamkanfi et al., 2007; 
Yu and Shi, 2008). It has been shown that c-FLIPL can function as a pro-apoptotic 
molecule at low levels of expression, promoting the activation of pro-caspase-8 at the 
DISC (Chang et al., 2002). In addition, Fricker et al. demonstrated that c-FLIPL exerts 
a pro-apoptotic role only under conditions of moderate expression along with strong 
receptor stimulation or with high amounts of c-FLIPS or c-FLIPR (Fricker et al., 
2010).  
Many tumors have been reported to express abnormally high levels of c-FLIP, such as 
melanoma (Bullani et al., 2001), colon carcinoma (Ryu et al., 2001), ATL (adult T-cell 
leukemia/lymphoma) (Krueger et al., 2006) and Hodgkin lymphoma (Thomas et al., 
2002), which correlates with resistance to apoptosis induced by CD95 or TRAIL. 
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Overexpression of c-FLIP in tumor cells also results in resistance to apoptosis induced 
by cytotoxic lymphocytes expressing CD95 ligand (French et al., 2002). In addition, 
high levels of c-FLIP expression in tumor cells were able to protect tumors from 
eradication by NK (natural killer) cells (Taylor et al., 2001). In contrast, c-FLIP 
knockdown in cells which express abnormaly high c-FLIP levels restores sensitivity 
to CD95 or TRAIL-mediated apoptosis (Krueger et al., 2006; Okamoto et al., 2006; 
Bleumink et al., 2010; Shirley et al., 2010). Finally, down-regulation of c-FLIP by 
various substances, such as doxorubicin, sodium butyrate and cycloheximide can 
overcome TRAIL resistance in tumor cells (Roth and Reed, 2004). Collectively, these 
data support the investigation of c-FLIP as a therapeutic target to restore an apoptotic 
response in cancer cells. 
 
1.1.3 The mitochondrial (intrinsic) apoptosis pathway 
The intrinsic apoptosis pathway, also called the mitochondrial pathway, can be 
initiated by different stress stimuli, such as DNA damage, oxidative stress, irradiation 
or cytotoxic drugs (Norbury and Zhivotovsky, 2004; Takahashi et al., 2004; Erlacher 
et al., 2005; Debatin and Krammer, 2004). As a result, the mitochondrial membrane is 
permeabilized leading to release of cytochrome c from mitochondria into the cytosol 
(Hockenbery et al., 1990). Subsequently, a protein complex called apoptosome is 
assembled which consists of Apaf-1 (apoptosis protease-activating factor 1), 
cytochrome c and pro-caspase-9 (Zou et al., 1999). Apaf-1 serves as an oligomerization 
platform for cytochrome c and caspase-9 in a dATP/ATP-dependent manner (Jiang et 
al., 2000). Apoptosome formation leads to the activation of caspase-9, subsequent 
activation of effector caspases, and finally to induction of cell death (Zou et al., 1999; 
Acehan et al., 2000).  
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1.1.4 Inhibitors and regulators of the intrinsic apoptosis pathway 
The Bcl-2 family: 
 
The most important regulators of the intrinsic apoptosis pathway are proteins of the 
Bcl-2 family. All members of the Bcl-2 family contain up to four characteristic 
regions termed the Bcl-2 homology domains (BH1-4). Most of the Bcl-2 members 
possess a hydrophobic transmembrane domain (TM) at the carboxyl-terminus (Fig. 
1.3). These proteins can be divided into two kinds: anti-apoptotic and pro-apoptotic 
proteins. 
 
 
Figure 1.3 The Bcl-2 family. The Bcl-2 family is made up of proteins that contain conserved 
functional BH (Bcl-2 homology) domains. These proteins can be divided into two kinds: 
anti-apoptotic and pro-apoptotic proteins. The latter can be further divided into multidomain 
effectors and BH3-only proteins. Some BH3-only proteins do not possess TM domain 
(transmembrane domain). Modified from (Giam et al., 2009) 
 
 
 
 
Anti-apoptotic members
Pro-apoptotic members
 
 
Introduction                
 25
ⅰ. The anti-apoptotic proteins of the Bcl-2 family: 
The anti-apoptotic proteins of the Bcl-2 family consist of Bcl-2, Bcl-xL, Bcl-w, Mcl-1 
and A1. They contain up to four BH domains and have similar three dimensional 
structures (Strasser, 2005). Overexpression of any of these anti-apoptotic Bcl-2 family 
members is able to prevent death induced by apoptotic stimuli, which indicates a 
functional redundancy between these proteins. However, in physiological conditions, 
it is unlikely that a single anti-apoptotic protein can ensure the survival of a cell 
population (Giam et al., 2009). These anti-apoptotic proteins are generally found at 
the outer membrane of mitochondria (OMM), where they function to inhibit the 
pro-apoptotic Bcl-2 proteins (Fletcher et al., 2008; Lindsay et al., 2010). It has also 
been shown that overexpression of anti-apoptotic proteins can block the release of 
cytochrome c to the cytosol, which inhibits apoptosome formation. However, the 
molecular mechanisms of this are still unclear (Giam et al., 2009). 
Mcl-1 (myeloid cell leukemia 1) is an anti-apoptotic member of the Bcl-2 family, 
which was initially identified as an immediate-early gene expressed in programmed 
myeloid cell differentiation (Kozopas et al., 1993). Mcl-1 contains three BH domains 
and its N-terminal region habours a potential regulatory motif which is predicted to 
regulate its function. Mcl-1 blocks the progression of apoptosis by binding and 
sequestering Bax and Bak which are capable of forming pores in the mitochondrial 
membrane, allowing the release of cytochrome c into the cytoplasm. Mcl-1 also binds 
and sequesters a subset of the BH3-only pro-apoptotic Bcl-2 family members, which 
act to induce the oligomerization of Bak and Bax (Thomas et al., 2010). Although 
Mcl-1 is one of the essential anti-apoptotic factors in the development and 
maintenance of normal cells, such as B and T-lymphocytes (Opferman et al., 2003)   
and neural development (Arbour et al., 2008), Mcl-1 overexpression has been found 
in a variety of human hematopoietic (Aichberger et al., 2005; Cho-Vega et al., 2004) 
and solid tumors (Derenne et al., 2002; Sieghart et al., 2006). Furthermore, 
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down-regulation of Mcl-1 overcomes Mcl-1-mediated resistance to conventional 
cancer therapy-induced apoptosis (Nguyen et al., 2007; Hussain et al., 2007; Paoluzzi 
et al., 2008; Wertz et al., 2011). In addition, Mcl-1 has been reported to contain two 
PEST sequences at the N-terminal region which are the targets for proteolysis by 
proteasome (Derouet et al., 2006; Akgul, 2009). Therefore, Mcl-1 has a very short 
half-life and inhibition of its expression will rapidly make Mcl-1-dependent tumor 
cells more susceptible to apoptosis and provide a therapy option for these cancers. 
 
ⅱ. The pro-apoptotic proteins of the Bcl-2 family: 
 
Multidomain effectors-Bax, Bak: 
 
Bax and Bak are the main effectors of the Bcl-2-regulated pathway. In response to 
cytotoxic signals, Bax and Bak change their conformation and form 
membrane-associated homo-oligomers. These oligomers are thought to form pores in 
the OMM and cytochrome c is released from permeabilized mitochondria. However, 
the molecular mechanism of pore formation still remains elusive (Newmeyer and 
Ferguson-Miller, 2003; Green, 2005; Giam et al., 2009). It has also been reported that 
Bax and Bak can influence the shape of the mitochondria via effects on the 
mitochondrial fission /fusion machinery, but it is still unclear whether this machinery 
contributes to mitochondria membrane permeabilization (Adams and Cory, 2007; 
Westermann, 2010). Although Bax and Bak seem to have identical functions, their 
subcellular localization is different. Bax is largely a cytosolic protein, while Bak is an 
integral membrane protein at the OMM. When activated, Bax translocates to the 
mitochondria to form homo-oligomers (Giam et al., 2009; Adams and Cory, 2007).  
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BH3-only proteins: 
 
The well studied mammalian BH3-only proteins include Bad, Bid, Bim, Noxa and 
Puma/BBC3. These proteins are all pro-apoptotic and their overexpression can 
promote apoptotic death in many cell types. However, cell death induced by 
BH3-only proteins requires presence of Bax and Bak, which indicates that they are 
upstream of Bax and Bak in the apoptosis pathway (Zong et al., 2001; Giam et al., 
2009). All BH3-only proteins bind strongly to at least some anti-apoptotic members of 
the Bcl-2 family (Chen et al., 2005) (Fig. 1.4). In addition, Bim, Bid and Puma were 
found to interact with Bax to induce cell death (Giam et al., 2009). 
The death receptor pathway and the mitochondrial pathway are linked by the 
pro-apoptotic BH3-only family member Bid. Upon stimulation, Bid is cleaved by 
caspase-8 to a truncated form (tBid) which translocates to the mitochondria where it 
acts together with the pro-apoptotic Bcl-2 family members Bax and Bak to induce the 
intrinsic apoptosis pathway (Scaffidi et al., 1998).  
 
 
 
 
 
 
 
 
 
Figure 1.4 Differing binding profiles of BH3-only proteins. Bim, Puma and Bid bind to and 
inhibit all of the anti-apoptotic proteins of the Bcl-2 family, whereas Bad only inhibits Bcl-2, 
Bcl-xL and Bcl-w and Noxa suppresses Mcl-1 and A1 (Chen et al., 2005). 
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XIAP: 
In addition to the anti-apoptotic Bcl-2 members, XIAP (X-linked Inhibition of 
Apoptosis Protein), a 57 kDa protein, is an important inhibitor of the apoptotic 
pathway. XIAP consists of three major types of structural domains: the BIR 
(baculoviral IAP repeat) domain, the UBA (ubiquitin-associated) domain and the 
RING (really interesting new gene) domain (Blankenship et al., 2009). 
XIAP-mediated inhibition of executioner caspases-3 and -7 is the result of XIAP 
BIR2 binding to these caspases and blocking their active sites (Stennicke et al., 2002; 
Chai et al., 2001). XIAP binding to caspase-9 via the BIR3 domain prevents 
caspase-9 dimerization and inhibits its protease activity (Deveraux and Reed, 1999; 
Gewies, 2003; Mufti et al., 2007). XIAP function can be inhibited by the release of 
the mitochondrial proteins Smac/DIABLO (second mitochondria derived activator of 
caspase/direct IAP binding protein with low isoelectric point) into the cytoplasm 
where they bind to XIAP at precisely the same domains that mediate the interactions 
of XIAP with the caspases (Chai et al., 2000; Du et al., 2000). So far, several reports 
have shown that down-regulation of XIAP sensitizes various tumor cells towards 
TRAIL or CD95-induced apoptosis (Kim et al., 2004; Kim et al., 2005; Loeder et al., 
2010). 
 
1.2 TRAIL and cancer therapy  
1.2.1 TRAIL and TRAIL receptors 
TRAIL (Apo2L, CD253, TNFSF10) is a type II transmembrane protein of about 
34kDa, which belongs to the TNF superfamily and was identified by two groups in 
1995/1996 (Wiley et al., 1995; Pitti et al., 1996). Similar to most members of the TNF 
family, TRAIL can be cleaved by metalloproteases at the cell surface to form a soluble 
molecule (Mariani et al., 1998). Active TRAIL forms trimers and specifically binds to 
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five TRAIL receptors: two agonistic receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) 
and three decoy receptors (TRAIL-R3/DcR1, TRAIL-R4/DcR2 and OPG) (Pan et al., 
1997; Walczak et al., 1997; Degli-Esposti et al., 1997a; Degli-Esposti et al., 1997b) 
(Fig. 1.5). TRAIL-R1 and TRAIL-R2 contain two cysteine-rich extracellular 
ligand-binding domains and a cytoplasmic region (death domain DD), which is 
important for activation of the extrinsic apoptosis pathway after TRAIL binding. 
However, TRAIL-R3 is a glycosylphosphatidylinositol (GPI)-anchored membrane 
protein devoid of DD and TRAIL-R4 is a transmembrane receptor with a truncated 
DD. Therefore, both of them are thought to play a role in negatively regulating the 
action of TRAIL. OPG (osteoprotegerin) has the lowest affinity to TRAIL and its role 
is still not clear (Gonzalvez and Ashkenazi, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 TRAIL receptors. In humans five TRAIL receptors have been identified. Two of 
them, TRAIL-R1 and TRAIL-R2, are transmembrane proteins containing cytosolic death domains 
that activate the caspase cascade. The others function as decoy receptors, lacking the capacity to 
activate the cell death pathway. TRAIL-R3 is a GPI-linked protein devoid of death domain. 
TRAIL-R4 is a transmembrane protein containing a non-functional, truncated death domain. OPG 
has the lowest affinity to TRAIL and its role is still not clear. Modified from (Lavrik et al., 2005). 
TRAIL
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1.2.2 Cancer cell resistance to TRAIL 
TRAIL has been shown to be an activator of apoptosis in tumor cells while sparing 
non-malignant cells. Therefore, TRAIL is promising in cancer treatment (Walczak et 
al., 1999; Bruix et al., 2004; Abdulghani and El-Deiry, 2010). That TRAIL has cancer 
cell selectivity has been reported by using stepwise tumorigenic cellular systems. In 
these systems, normal cells which are resistant to TRAIL were transformed by ectopic 
expression of oncogenes Ras or c-Myc, and subsequently these cells showed restored 
sensitivity to TRAIL-induced cell death (Nesterov et al., 2004; Wang et al., 2005; 
Nieminen et al., 2007). However, various tumor cells show resistance to 
TRAIL-induced apoptosis (LeBlanc et al., 2003; Pan et al., 2007), such as prostate 
cancer cells (Kasman et al., 2006), human T-cell leukemia virus 1-infected T cells 
(Matsuda et al., 2005; Bleumink et al., 2010) and colon cancer cells (Ishii et al., 
2007). 
Several mechanisms could explain tumor cell resistance to TRAIL-induced apoptosis. 
One explanation is that aberrant expression of TRAIL receptors results in resistance to 
TRAIL-induced apoptosis in tumor cells. Impairment or mutation of TRAIL-R1 or 
TRAIL-R2 at the critical domains (such as DD or the ligand-binding domain) can 
hamper TRAIL-induced cell death (Kim et al., 2000; Park et al., 2001; Fisher et al., 
2001; McDonald et al., 2001). Decoy receptors (DcRs) may compete with death 
receptors for TRAIL binding (Pan et al., 1997; Degli-Esposti MA et al., 1997a; 
Degli-Esposti MA et al., 1997b, Mérino et al. 2007). Ectopic expression of DcRs in 
TRAIL-sensitive cells leads to TRAIL resistance, suggesting that DcRs are negative 
regulators of TRAIL-mediated apoptosis (Marsters et al., 1997; Mérino et al., 2006). 
Similarly, TRAIL sensitivity could be restored in resistant cells by using anti-DcRs 
blocking antibodies or siRNA to decrease DcR expression (Sanlioglu et al., 2005; 
Sanlioglu et al., 2007).  
Another explaination for tumor cell resistance to TRAIL-induced apoptosis is that 
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DISC level deficiency in caspase-8 and -10, caused by a loss-of-function mutation or 
gene promoter methylation, impairs TRAIL-induced apoptosis (Fulda et al., 2001; 
Hopkins-Donaldson et al., 2003; Cheng et al., 2006). Aberrantly increased expression 
of c-FLIP is another reason for TRAIL resistance at the DISC level. Various tumors 
have been reported to express abnormally high levels of c-FLIP, such as melanoma 
(Bullani et al., 2001), colon carcinoma (Ryu et al., 2001) and ATL (adult T-cell 
leukemia/lymphoma) (Bleumink et al., 2010), which correlates with resistance to 
apoptosis induced by TRAIL. c-FLIP knockdown in cells which express abnormal 
high c-FLIP levels restores sensitivity to TRAIL-mediated apoptosis (Bleumink et al., 
2010; Shirley et al., 2010). Down-regulation of c-FLIP by various substances, such as 
doxorubicin, sodium butyrate and cycloheximide can also overcome TRAIL 
resistance in tumor cells (Roth and Reed, 2004). Therefore, c-FLIP is a therapeutic 
target to restore TRAIL sensitivity in cancer cells. 
Furthermore, the Bcl-2 family members have been shown to be major regulators of 
the intrinsic apoptosis pathway. Impaired expression of the pro-apoptotic members of 
the Bcl-2 family, such as Bax (LeBlanc et al., 2002), or overexpression of 
anti-apoptotic proteins of the Bcl-2 family, such as Bcl-2 (Fulda et al., 2002), can lead 
to TRAIL resistance. In addition, IAPs which inhibit caspase activities have also been 
reported to play a role in TRAIL resistance (Hersey et al., 2003; Straub, 2010).  
 
1.2.3 Sensitization of cancer cells to TRAIL 
Besides the resistance of human tumor cells to TRAIL-induced apoptosis, two other 
limitations hamper its use in the clinic. First, during the use of TRAIL in a Phase I 
clinical trial (Genentech and Amgen), it was revealed that TRAIL is rapidly cleared 
from the circulation, thus a prolonged administration or a sensitizer may be required 
for its anti-tumor activity (Mérino et al., 2007). Second, TRAIL rarely showed a 
 
 
Introduction                
 32
complete eradication of established tumors in xenografted animal models. These facts 
strengthen the necessity of combining TRAIL with other compounds or molecules to 
sensitize tumor cells to TRAIL-induced cell death. 
Combination treatment of TRAIL with chemotherapeutic drugs, such as paclitaxel, 
vincristine, vinblastine and etoposide, could exploit synergistic properties inducing 
apoptosis and regression in tumors (Singh et al., 2003; Buchsbaum et al., 2006; 
Abdulghani and El-Deiry, 2010). In vivo, such combination treatment of TRAIL and 
chemotherapeutics in immunodeficient mice results in the regression of xenografted 
human tumors, such as breast carcinoma and colon carcinoma (Naka 2002; Singh et 
al., 2003). Chemotherapeutic agents were shown to sensitize tumor cells to 
TRAIL-induced apoptosis by several mechanisms such as death receptor 
up-regulation and anti-apoptotic protein down-regulation (Wu et al., 2004; Mérino et 
al., 2007; Abdulghani and El-Deiry, 2010). 
Another approach is the combination of ionizing radiation and TRAIL, which was 
shown to sensitize breast cancer (Chinnaiyan et al., 2000), leukemic (Gong et al., 
2000), melanoma (Ivanov et al., 2007) and glioma (Ciusani et al., 2005) cells to 
TRAIL-induced cell death. The suggested mechanisms of the synergistic effect 
through combination of radiation and TRAIL are p53-dependent up-regulation of 
TRAIL-R2, Bax and Bak induction and suppression of Bcl-2 (Shankar et al., 2004; 
Rahman et al., 2009). 
Non-toxic compounds derived from natural food products or plants have also been 
demonstrated to synergize with TRAIL therapy. For example, Rocaglamide, derived 
from the traditional Chinese medicinal plant Aglaia, breaks TRAIL resistance in 
HTLV-1-associated ATL by translational suppression of c-FLIP expression (Bleumink 
et al., 2010). Resveratrol, present in grapes, was demonstrated to enhance TRAIL 
anti-tumor activity in colon carcinoma cells through redistribution of death receptors 
in lipid rafts which increases signaling efficiency (Delmas et al., 2004). 
Additional molecules are also able to sensitize tumor cells TRAIL-induced apoptosis. 
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For example, synthetic triterpenoids sensitize AML (acute myeloid leukemia) and 
breast cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIP (Suh et 
al., 2003; Hyer et al., 2005). Several protein inhibitors have been reported to sensitize 
resistant tumor cells to TRAIL-induced cell death, such as proteasome inhibitors, 
Hsp90 inhibitors and anti-apoptotic Bcl-2 family inhibitors (Mérino et al., 2007; 
Kruyt, 2008). 
 
1.2.4 TRAIL-R2, a transcriptional target of p53, Sp1 and CHOP 
As mentioned above, up-regulation of TRAIL-R2 can be a mechanism for 
sensitization of resistant tumor cells to TRAIL-induced apoptosis. It has been shown 
that several agents, such as potent anti-cancer natural compound triptolide, the 
antibiotic tunicamycin and histone deacetylase sodium butyrate can sensitize certain 
cancer cells to TRAIL-mediated apoptosis through p53, CHOP 
(CCAAT/enhancer-binding protein homologous protein) or Sp1-mediated 
up-regulation of TRAIL-R2, respectively (Shiraishi et al., 2005; Yoshida et al., 2005; 
Carter et al., 2008; Kim et al., 2004; Kim et al., 2010). CHOP, Sp1 and p53 are 
transcription factors which can bind to the TRAIL-R2 promoter and regulate 
TRAIL-R2 expression. The CHOP binding site is located at -270 bp of the TRAIL-R2 
promoter and the promoter region contains four putative Sp1 binding sites (Yoshida et 
al., 2001). In addition, three p53 DNA-binding sites have been identified in the 
TRAIL-R2 genomic locus and intron 1 (+ 0.25 Kb downstream of the ATG) is 
responsible for the p53-dependent transactivation of TRAIL-R2 (Takimoto et al., 
2000).  
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1.2.5 p53 and MDM2   
The p53 tumor suppressor protein serves as a genome guardian and has been studied 
for nearly 30 years (Levine and Oren, 2009; Vousden and Prives, 2009). It functions 
mainly as a transcription factor by binding to specific DNA sequences to transactivate 
or repress a large group of target genes (el-Deiry et al., 1992; Laptenko and Prives, 
2006). In response to different stimuli, such as DNA damage, hypoxia or deficiency 
of growth factors or nutrients, p53 binds to its downstream targets to regulate the 
pathways of cell cycle arrest, apoptosis and DNA repair to maintain a dynamic 
equilibrium between cell growth and arrest (Mandinova and Lee, 2011).   
The p53 activity is strictly controlled by a negative regulator termed MDM2 (mouse 
double minute 2). MDM2 was originally found in a mouse tumor cell line with 
enhanced MDM2 expression (Fakharzadeh et al., 1991). Later it was proven that 
MDM2 interacts with p53 and negatively regulates its function. So far, two 
mechanisms have been reported for MDM2-mediated negative regulation of p53 
(Manfredi, 2010). One mechanism is that MDM2 directly binds to the N-terminal end 
of p53 to inhibit the transactivating function of p53. Another one is that the E3 
ubiquitin ligase activity of MDM2 targets p53 for ubiquitination and subsequent 
degradation by the 26S proteasome. Both p53 and MDM2 are molecules with short 
half-life. p53 protein usually has a half-life of about 20 min (Weinberg, 2006), and the 
p53 mRNA half-life is about 4 to 6 h (Zhao et al., 2008; Mazan-Mamczarz et al., 
2003). MDM2 mRNA and protein half-life was estimated to be about 20 to 40 min 
(Wang et al., 2002; Itahana et al., 2007).  
MDM2 can function as an oncogene by down-regulation of p53. Additionally, it has 
been shown that MDM2 acts as an oncogene through p53-independent mechanisms 
which regulate proliferation, apoptosis and the epithelial-to-mesenchymal transition. 
As an example, overexpression of MDM2 caused mammary epithelial cells to 
undergo multiple rounds of S phase without cell division both in p53 wild type and 
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p53 knockout mice, suggesting that MDM2 regulation of cell cycle progression is 
independent of p53 (Lundgren et al., 1997). Additionally, MDM2 has also been 
shown to prevent apoptosis by binding to the mRNA of the anti-apoptotic protein 
XIAP, thereby enhancing XIAP translation and expression (Gu et al., 2009). Most 
notably, MDM2 has been reported to modify E-cadherin for degradation via the 26S 
proteasome, which leads to the epithelial-to-mesenchymal transition, a vital step of 
metastasis in solid tumors of epithelial origin (Yang et al., 2006; Thiery et al., 2009). 
All these findings demonstrate that MDM2 may act as an oncogene independently of 
p53.  
In recent years, a diverse range of p53-targeting drugs have been developed. 
Remarkably, two drugs named RITA and nutlin have been shown to stabilize 
wild-type p53 through inhibition of the MDM2-p53 interaction and protection of p53 
form being degraded by the ubiquitin-proteasome system. RITA directly binds to p53 
and interferes with the interaction of MDM2 and p53, whereas nutlin fits in the 
p53-binding pocket of MDM2, effectively dislodging p53 from MDM2 (Levine and 
Oren, 2009). 
 
1.3 Human T-cell leukemia/lymphoma virus-1 (HTLV-1) 
1.3.1 Introduction to HTLV-1 
HTLV-1, a member of the delta-retrovirus family, is the first retrovirus shown to be 
directly associated with a human malignancy. It was isolated from fresh and cultured 
lymphocytes of a patient with cutaneous T-cell lymphoma (Mycosis fungoides) by 
Robert Gallo’s group at the NIH (National Institutes of Health) in 1980 (Poiesz et al., 
1980). In 1982, Mitsuaki Yoshida and his colleagues in Japan identified the etiologic 
agent of ATL (adult T-cell leukemia) and named the virus adult T-cell leukemia virus 
(ATLV) (Yoshida et al., 1982). Later HTLV and ATLV were demonstrated to be the 
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same retrovirus based on homology of the viral genome and viral antigens. The terms 
were unified to HTLV-1 (Watanabe et al., 1984).  
Currently, 15 to 20 million people all over the world are infected with HTLV-1 
(Matsuoka and Jeang, 2010). HTLV-1 is endemic in south-western Japan, the 
Caribbean, the Middle-East, inter-tropical Africa and South-America. The highest 
prevalence rate in the general population is 10% in the south of Japan (Proietti et al., 
2005). HTLV-1 infects many cell types in vitro, but in vivo it is detected mainly in 
CD4+ T cells and to a lesser extent in CD8+ T cells and dendritic cells (Matsuoka and 
Jeang, 2010). HTLV-1 needs cell to cell contact for transmission, which takes place 
upon forming of a virological synapse between infected and non-infected cells 
(Nejmeddine et al., 2005). HTLV-1 can be transmitted in three ways: mother-to-child 
transmission, sexual intercourse, contaminated blood cell transfusion or 
needle-sharing between intravenous drug users (Proietti et al., 2005). 
 
1.3.2 HTLV-1 genome and persistence  
HTLV-1 contains a relatively small genome (9 kb) but expresses multiple gene 
products due to transcription of both strands of its pro-viral genome and mRNA 
alternative splicing. The gag, pol (polymerase) and env (envolpe protein) genes are 
flanked by 5’ and 3’ long terminal repeats (LTRs). In the 3’ portion of the genome 
between the env gene and the 3’ LTR, is a “pX region” which contains four partially 
overlapping reading frames (ORFs) encoding the accessory proteins (p12I, p13II, 
p30II), the post-transcriptional regulator p21REX (ORF III) and the TAX 
transactivator (ORF IV) (Seiki et al., 1983). In addition, HTLV-1 basic leucine zipper 
factor (HBZ) is encoded from 3’ LTR in the complementary strand of the genome 
(Gaudray et al., 2002) (Fig. 1.6).  
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Figure 1.6 HTLV-1 pro-viral genome. HTLV-1 genome contains both a 5'LTR and a 3'LTR, 
between which the genome encodes the structural proteins, gag, pol, env and pX. In pX region, the 
viral proteins, p12I, p13II, p21rex, p30II and Tax are encoded. The HBZ minus strand RNA and 
protein are synthesized in an antisense fashion from the 3' LTR. Superscript Roman numerals 
indicate the respective open reading frame used for the translation of the indicated protein.  
 
Homologues of the proteins Gag, Pol and Env are also found in other retroviruses, 
such as human immunodeficiency virus (HIV), and are required for virus replication 
and virion formation (Green et al., 2005). The regulatory proteins p12, p30, p13 and 
HBZ are involved in virus infectivity, immune escape and the establishment of a 
latent state (Nicot et al., 2005). Rex is an RNA-binding post-transcriptional regulator 
which specifically binds to the Rex response element (RRE) located at the 3’ region 
of the viral mRNA to promote the transport of the unspliced and singly spliced viral 
RNA from nucleus to the cytoplasm to express structural proteins (Kashanchi et al., 
2005). Among all these regulatory proteins, the most studied viral proteins are Tax 
and HBZ and they appear to have particularly important roles in viral persistence and 
pathogenesis.  
Tax (p40) is an activator of transcription that binds to triplicate enhancer elements 
(TRE) located in the 5’ LTR, which has been shown to be essential for the replication 
of HTLV-1 (Chlichlia and Khazaie, 2010). Importantly, this trans-acting factor also 
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acts as a potent transcriptional regulator of cellular gene expression. 
Tax can transcriptionally activate the expression of cellular genes involved in growth 
and proliferation pathways, such as Akt and NF-κB pathways, to inhibit apoptosis 
(Taylor et al., 2008). Several anti-apoptotic proteins are up-regulated by Tax-mediated 
NF-κB activation, such as Bcl-xL (Mori et al., 2001; Tsukahara et al., 1999), IAP 
family proteins (Kawakami et al., 1999; Waldele et al., 2006) and c-FLIP (Micheau et 
al., 2001; Kreuz et al., 2001). In addition, Tax is able to prevent Bax relocation to 
mitochondria (Trevisan et al., 2006).  
Furthermore, Tax inhibits tumor suppressor proteins, such as retinoblastoma (Rb) 
protein, which is phosphorylated to promote cell transition from G1 to S phase of the 
cell cycle (Kehn et al., 2005; Chlichlia and Khazaie, 2010). Tax also negatively 
regulates transcription of the tumor suppressor p53 (Mahieux et al., 2000; 
Pise-Masison et al., 2000; Chlichlia and Khazaie, 2010).  
The HBZ gene is transcribed as an anti-sense transcript of HTLV-1 from the 3' LTR. It 
has been reported that the Tax gene transcripts are detected in only about 40% of 
transformed ATL cells. However, the HBZ gene is ubiquitously expressed in all ATL 
cells and supports proliferation of adult T cell leukemia cells (Satou et al., 2006; 
Chlichlia and Khazaie, 2010). In addition, HBZ gene expression is well correlated 
with the amount of integrated provirus in HTLV-1-infected individuals (Matsuoka 
and Jeang, 2010). Therefore, one hypothesis is that Tax and HBZ may cooperate in 
the process of leukemogenesis. Tax initiates the transformation process and HBZ 
supports survival of the infected cells (Chlichlia and Khazaie, 2010; Matsuoka and 
Jeang, 2010). 
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1.3.3 HTLV-1 associated diseases 
ATL (adult T-cell leukemia/lymphoma) is a peripheral T-cell malignancy caused by 
HTLV-1 (Poiesz et al., 1980; Hinuma et al., 1981). The probability of infected people 
to develop ATL is 2-5 %. There is a long latency period between infection and the 
appearance of ATL, which is as much as 60 years in Japan and 40 years in Jamaica 
(Yasunaga et al., 2007). A clinical feature of ATL is leukemic cells with flower-like 
nuclei called ‘flower cells’. The immunological phenotype of ATL cells is 
CD3+CD4+CD8-CD25+ and 59% of ATL cases express the transcription factor 
forkhead box P3 (FOXP3), suggesting that some ATL T cells originate from 
virus-infected Treg cells (Karube et al., 2004). ATL has four clinical subtypes: acute, 
lymphoma, chronic and smoldering. The first two types are very aggressive and there 
is no efficient treatment so far. The chronic and smoldering forms of ATL are indolent, 
but after a number of years they will develop into the acute forms (Shuh et al., 2005). 
Currently, patients in acute and lymphoma phase are treated with CHOP 
(cyclophosphamide, hydroxydoxorubicin, vincristine and prednisolone), AMP 
(doxorubicin, ranimustine and prednisolone) or VECP (vincristine, etoposide, 
cyclophosphamide and prednisolone) chemotherapy regimens. Other treatment 
strategies are described in the literature, such as NF-κB pathway blockers and PI3K 
inhibitors. Although these treatment strategies offer some treatment options, the 
mortality rate is still very high (Tsukasaki et al., 2009; Romanelli et al., 2010). 
In addition to ATL, HTLV-1 was also reported to be related to tropical spastic 
paraparesis (TSP) (Gessain et al., 1985) and HTLV-associated myelopathy (HAM) 
(Osame et al., 1986). Later, these two diseases were found to be the same disease 
(Román and Osame, 1988). More recently, several other diseases such as thyroiditis 
and Sjögren’s syndrome have been correlated with this retrovirus infection (Seguchi et 
al., 2006; Verdonck et al., 2007; Cooper et al., 2009). 
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1.3.4 p53 mutation in HTLV-1-associated ATL 
p53 mutations are found in 50% of human cancers (Sossi and Wiman, 2007). These 
mutations occur at variable frequencies in different tumor types. For instance, small 
cell lung cancer and ovarian carcinoma have the highest occurrence of p53 mutation, 
while testis cancer rarely shows mutant p53 (Olivier et al., 2002). The p53 status in 
ATL patients has been studied by several groups. These studies have shown that p53 
is mutated especially in patients with acute ATL rather than in patients with chronic 
ATL. In addition, it was suggested that p53 mutations may be involved in the 
transition from chronic to acute stage of ATL (Nagai et al., 1991; Sakashita et al., 
1992; Yamato et al., 1993; Tabakin-Fix et al., 2006). In contrast, p53 shows wild type 
sequence in most of HTLV-1-associated ATL cell lines, but its function is inhibited 
by the HTLV-1 Tax protein through the activation of the NF-κB pathway 
(Pise-Masison et al., 2000; Jeong et al., 2004). The anti-cancer drug 9-aminoacridine 
(9AA) has been reported to inhibit NF-κB and to induce p53 activity in 
HTLV-1-transformed cells, leading to a dramatic decrease in cell viability (Jung et al., 
2008). This suggests a promising strategy for the treatment of HTLV-1 related 
diseases. 
 
1.4 Wogonin and its analogs 
The great potential of natural agents for cancer treatment is becoming more and more 
evident and consequently much effort is being made to identify promising candidates. 
In this study, Wogonin and its two analogs Apigenin and Chrysin were tested for their 
effects on sensitization to TRAIL-induced apoptosis in HTLV-1-associated ATL cell 
lines. These three compounds belong to a subgroup of flavonoids, named flavones 
(2-phenyl-chromone), which are composed of two benzene rings (A and B) joined 
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together by a γ-pyrone ring (C ring) (Li-Weber, 2010; Khoo et al., 2010) (Fig. 1.7).  
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Basic structure of flavones and structures of Wogonin, Apigenin and Chrysin. 
 
Wogonin (5, 7-dihydroxy-8-methoxyflavone) is an active compound extracted from 
Huang-Qin (Scutellaria baicalensis Georgi) (Fig. 1.7). Huang-Qin is a herb used in 
traditional Chinese medicine for treatment of hyperlipemia, hypertension, dysentery, 
the common cold and inflammatory diseases. Wogonin has been reported to have 
anti-oxidant, anti-viral, anti-inflammatory and anti-thrombotic activities (Chang et al., 
2001; Li-Weber, 2009; Li-Weber, 2010). Wogonin induces cell death in various 
human tumor cells in vitro and inhibits tumor growth in vivo in several tumor-bearing 
mouse models (Li-Weber, 2010). Recently, our group has shown that Wogonin 
attenuates NF-κB activity by shifting TNFα-induced free radicals ·O2– to a more 
reduced nonradical product, H2O2, and thereby sensitizes TNFα-resistant leukemia 
cells to TNFα-induced apoptosis. In addition, Wogonin overcomes TRAIL resistance 
in primary AML (acute myeloid leukemia) cells. However, the molecular mechanisms 
need to be further investigated (Fas et al., 2006). Wogonin has also been reported to 
recover TRAIL sensitivity in resistant prostate cancer cells by reactive oxygen species 
(ROS) dependent up-regulation of p53 and Puma (Lee et al., 2009). Furthermore, it 
Basic structure of flavones
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has been shown that Wogonin potentiates the anti-tumor effects of several 
chemotherapeutics and ameliorates their adverse effects, such as etoposide and 
5-fluorouracil (Enomoto et al., 2010; Zhao et al., 2010). Recently, our group found 
that Wogonin blocks transcription in cancer cells by inhibiting CDK9 
(cyclin-dependent kinase 9) which plays a major role in regulation of transcription 
(Polier et al., unpublished data). 
Importantly, Wogonin does not affect the viability of peripheral blood T cells derived 
from healthy donors (Fas et al., 2006). Moreover, it has been reported that Wogonin 
offers a wide margin of safety and shows no organ toxicity following long term 
intravenous administration in Beagle dogs (Peng et al., 2009). Toxicological studies of 
Wogonin in albino mice or Sprague-Dawley rats suggested that it is a safe and 
promising anti-cancer agent (Qi et al., 2009). 
Apigenin is chemically known as 4’ 5, 7, -trihydroxy-flavone (Fig. 1.7). It is 
abundantly present in common vegetables, such as onions and parsley, fruits, such as 
oranges and grapefruit and plant derived beverages, such as tea (Birt et al., 2001; Surh 
et al., 2003). For centuries Apigenin has been used as a traditional medicine to treat 
asthma, intransigent insomnia, Parkinson’s disease and shingles (Patel et al., 2007). 
So far a variety of studies have shown that apigenin possesses anti-oxidant, 
anti-carcinogenic and anti-inflammatory activities (Shukla et al., 2007; Li-Weber, 
2010). 
Chrysin (5, 7-dihydroxy-2-phenyl-4H-chromen-4-one) is another natural active 
compound extracted from honey, propolis and plants (Fig. 1.7). It is an analog of 
Apigenin (Sanderson et al., 2004) and shares the common flavone structure with 
additional hydroxyls at positions 5 and 7 of the benzene ring A. It has been reported 
that Chrysin shows anti-inflammatory, anti-viral and anti-oxidant effects as well as 
anti-cancer activity by induction of apoptosis in a diverse range of human and rat 
cancer cells (Cho et al., 2004; Woodman et al., 2004; Khoo et al., 2010; Li-Weber, 
2010). 
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1.5 Aim of the study 
Targeting apoptosis pathways is one of the key strategies for cancer treatment. TRAIL, 
which is considered as a promising anti-cancer agent, triggers apoptosis in a variety of 
tumor cells but not in non-malignant cells. However, 50 % of tumor types show 
resistance to TRAIL-induced apoptosis, including HTLV-1-associated ATL. So far 
various treatment strategies are offered to ATL patients, but because of apoptosis 
resistance the mortality of ATL is still very high. 
Our lab has previously shown that Wogonin, derived from the Traditional Chinese 
Medicine (TCM) plant Huang-Qin (Scutellaria baicalensis Georgi), attenuates NF-κB 
activity by shifting TNFα-induced free radicals ·O2– to a more reduced nonradical 
product, H2O2, and thereby sensitizes TNFα-resistant leukemia cells to TNFα-induced 
apoptosis. In addition, Wogonin overcomes TRAIL resistance in primary AML (acute 
myeloid leukemia) cells. Importantly, Wogonin does not affect the viability of 
peripheral blood T cells derived from healthy donors. However, the mechanisms of 
Wogonin-mediated sensitization of TRAIL-induced apoptosis are still not known.  
In this study, HTLV-1-associated ATL cell lines SP, MT-2 and MT-4 are used to 
investigate resensitization resistant tumor cells to TRAIL-induced apoptosis. These 
cell lines are found to express a high level of the anti-apoptotic protein c-FLIP which 
blocks death receptor-mediated apoptosis at the DISC level. Therefore, the natural 
herbal compound Wogonin is tested for its activity to down-regulate c-FLIP and to 
sensitize HTLV-1-associated ATL cells to TRAIL-induced cell death. The molecular 
mechanisms of TRAIL resensitization by Wogonin in HTLV-1 ATL cells are further 
investigated. The aim of this study is to find a new approach to overcome resistance 
of HTLV-1-associated ATL cells to TRAIL-mediated apoptosis. The final goal is to 
develop a strategy for the treatment of ATL and other types of TRAIL resistant 
tumors.  
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2. MATERIALS AND METHIODS 
2.1 Materials 
2.1.1 Chemicals 
All chemicals, unless specified, are purchased from Merck (Darmstadt), Roth 
(Karlsruhe), Fluka (Neu-Ulm), Sigma (München) and Serva (Heidelberg). 
2.1.2 Buffers and solutions 
Name 
PBS:   
 
 
 
 
PBST:   
 
 
Nicoletti lysis buffer: 
 
 
 
TBE (10 ×):   
 
 
 
 
 
Concentration 
137 mM 
8.1 mM 
2.7 mM 
1.5 mM 
 
 
0.5 % (v/v) 
 
0.1 % (w/v)    
0.1 % (v/v)    
50 μg/ml       
 
0.45 M         
0.45 M         
10 mM 
 
 
 
Reagents 
NaCl 
Na2HPO4 
KCl 
KH2PO4, pH 7.4 
 
PBS 
Tween 20 
 
Na-citrate 
Triton X-100 
Propidium iodide 
 
Tris-Base 
Boric acid 
EDTA, pH 8.3 
(Ethylene-diamine-tetra-actetate) 
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RIPA lysis buffer: 
 
 
      
 
 
 
 
 
 
 
 
 
Blocking buffer:   
 
SDS sample buffer (5 ×): 
 
 
 
 
 
Running buffer (SDS-PAGE): 
 
 
 
 
 
 
50 mM    
1 % 
0.5 % 
120 mM 
2 mM   
0.1 % 
1 × 
 
1 mM 
200 μM 
25 mM 
1 mM 
 
5 % (w/v) 
 
50 mM 
10 % (w/v) 
50 % (v/v) 
0.25 mg/ml   
25 % (v/v) 
 
0.19 M    
0.1 % (w/v) 
25 mM 
 
 
 
 
Tris-HCl, pH 8.0 
NP-40 
Na-deoxycholate 
NaCl 
EDTA 
SDS (Sodium-dodecyl-sulfate) 
Protease Inhibitor Cocktail 
(Roche) 
DTT 
Na3VO4  
NaF 
PMSF 
 
Non-fat dry milk in PBST 
 
Tris-Base, pH 6.8 
SDS 
Glycerol 
Bromophenol blue 
β-Mercaptoethanol (β-ME) 
 
Glycin 
SDS 
Tris-Base, pH 6.8 
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Transfer buffer (Western blot):  
 
 
 
 
Laemmli Resolving gel: 
 
 
 
 
 
 
 
Laemmli Stacking gel (5%): 
 
 
25 mM 
0.19 M 
20 % (v/v) 
0.037 % (w/v) 
 
37.5 mM 
5-15 % (w/v) 
 
0.1 % (w/v) 
0.03 % (w/v) 
0.1 % (w/v) 
 
 
24 mM 
5 % (w/v) 
 
0.1 % (w/v) 
0.1 % (w/v) 
0.1 % (w/v) 
Tris-Base 
Glysin 
Methanol 
SDS 
 
Tris-Base, pH 8.8 
Acrylamide/Bisacrylamide 
37.5:1 
SDS 
Ammonium persulfate (APS) 
Tetramethylethylendiamine 
(TEMED) 
 
Tris-Base, pH 6.8 
Acrylamide/Bisacrylamide 
37.5:1 
SDS 
APS 
TEMED 
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2.1.3 Reagents 
Name  
SuperKiller TRAIL 
Wogonin 
Apigenin 
Chrysin 
Uracil-N-Glycolase 
Trypsin-EDTA (1x) 
Supplier 
Alexis 
BIOTREND 
Sigma 
Sigma 
Eurogentec 
Sigma 
 
2.1.4 Eukaryotic cell lines 
Cell line    
Jurkat 16 (J16) 
CEM 
SP 
MT-2 
MT-4 
Hep3b 
HepG2 
PC3 
MDA-MB-231 
HT-29 
SK-MEL-37 
Description 
Human acute lymphoblastoid T cell line 
Human acute lymphoblastoid T cell line 
HTLV-1-associated ATL cell line 
HTLV-1-associated ATL cell line 
HTLV-1-associated ATL cell line 
Human hepatoma cell line 
Human hepatoma cell line 
Human prostate cancer cell line 
Human breast cancer cell line 
Human colon cancer cell line 
Human melanoma cell line 
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2.1.5 Culture medium for eukaryotic cell lines 
Cell line 
Jurkat 16 (J16) 
CEM 
MT-2 
MT-4 
PC3 
MDA-MB-231 
HT-29 
SK-MEL-37 
Culture media 
RPMI 1640 (Sigma) 
RPMI 1640 (Sigma) 
RPMI 1640 (Sigma) 
RPMI 1640 (Sigma) 
RPMI 1640 (Sigma) 
RPMI 1640 (Sigma) 
DMEM (Sigma) 
DMEM  
SP RPMI 1640 with 100 U/ml IL-2 
Hep3b MEM (Sigma) 
HepG2 DMEM  
 
Media were supplemented with 1 % (v/v) Penicillin-Streptomycin (Sigma), 2 mM 
L-glutamine (Invitrogen) and 10 % (v/v) FBS (Fetal Bovine Serum). FBS was 
purchased from GIBCO. 
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2.1.6 Antibodies for Western blot analysis 
Antigen 
α-tubulin  
Bcl-2 
Bcl-xl 
Bad 
Bak 
Bax 
Bid 
Caspase-2 
Caspase-3 
Caspase-8 p18 (C15) 
Caspase-9 
c-FLIP (NF-6) 
CHOP 
ERK (MK-12) 
FADD 
p53 (1C12) 
TRAIL R1 
TRAIL R2 
TRAIL R3 
TRAIL R4 
Mcl-1 
Sp1 (PEP2) 
XIAP 
Origin 
Sigma 
Santa Cruz 
Cell signaling 
Cell signaling 
Cell signaling 
BD (Biosciences) 
Cell signaling 
Cell signaling 
Cell signaling 
Scaffidi et al., 1997  
Santa Cruz 
Scaffidi et al., 1999  
Santa Cruz 
BD 
Transduction Laboratories 
Cell signaling 
ProSci 
Cell signaling 
Cell signaling 
Cell signaling 
Santa Cruz 
Santa Cruz 
Cell signaling 
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2.1.7 Antibodies for flow cytometer analysis 
Name Origin 
TRAIL-R1 
TRAIL-R2 
TRAIL-R3 
TRAIL-R4 
Mouse IgG1, FITC conjugated 
Goat anti-mouse IgG1, FITC conjugated 
Alexis, HS101(IgG1) 
Alexis, HS201(IgG1) 
Alexis, HS301(IgG1) 
Alexis, HS401(IgG1) 
USBio 
Alexis 
2.1.8 Primers 
Target gene Sequence 
c-FLIPL forward 
c-FLIPL reverse 
c-FLIPL probe 
c-FLIPS forward 
c-FLIPS reverse 
c-FLIPS probe 
5’-GGC TCC CCC TGC ATC AC-3’ 
5’-TTT GGC TTC CCT GCT AGA TAA GG-3’ 
5’-CAG GAG GAT GTT CAT GGG AGA TTC ATG C-3’  
5’-ACC CTC ACC TTG TTT CGG ACT AT-3’ 
5’-TGA GGA CAC ATC AGA TTT ATC CAA A-3’ 
5’-AGA GTG CTG ATG GCA GAG ATT GGT GAG G-3’ 
p53 forward 
p53 reverse 
p53 probe 
5’-GCC CCC AGG GAG CAC TA-3’ 
5’-GGG AGA GGA GCT GGT GTT G-3’ 
5’-TTG GGC AGT GCT CGC T-3’ 
MDM2 forward 
MDM2 reverse 
MDM2 probe 
5’-ATG TCT GTA CCT ACT GAT GGT GCT G-3’ 
5’-TCA AAA GCA ATG GCT TTG GTC T-3’ 
5’-CCA CCT CAC AGA TTC CAG CTT CGG A-3’ 
18S rRNA forward 
18S rRNA reverse 
18S rRNA probe  
5’-GTG ACG GAG AAT TAG GGT TCG A-3’ 
5’-CTG CCT TCC TTG GAT GTG GTA-3’ 
5’-CCG GAG AGG GAG CCT GAG AAA CGG-3’ 
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TRAIL-R2 forward 
TRAIL-R2 reverse 
GAPDH forward 
GAPDH reverse 
5'-TGG TTC CAG CAA ATG AAG GTG-3' 
5'-CCG CTG CCT CAG CTT TAG C-3' 
5’-ACA TCA AGA AGG TGG TGA AGC AGG-3’ 
5’-CTC TTG CTC TCA GAT CCT TGC TGG-3’ 
 
Probes were all conjugated with FAM at the 5’ end and TAMRA at the 3’ end. p53, 
MDM2, 18S rRNA, TRAIL-R2 and GAPDH primers were described previously 
(Baumbusch et al., 2006; Wilda et al., 2004; Osman et al., 2008; Sun et al., 2008; 
McCullough et al., 2001). 
2.1.9 Kits 
Kit Origin 
RT PCR Kit 
PCR-Taqman Kit 
PCR-SYBR Green Kit  
RNeasy Mini Kit  
Gel extraction Kit 
Applied Biosystems 
Eurogentec 
Eurogentec 
Qiagen 
Qiagen 
2.1.10 Instruments 
Instrument 
Flow cytometer FACScan  
Thermocycler 
UV transilluminator 
Agarose gel electrophoresis apparatus 
Microwave oven HMG 730B  
Laminar chambers  
Semi-Dry blotting system 
Manufacturer 
Becton Dickinson 
Perkin Elmer 
Bio-Rad 
Gibco BRL 
Bosch 
Bio-Rad  
Bio-Rad/PEQLab 
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Cell culture incubator  
Cell culture hood 
Neubauer Cell-counting chamber  
Light microscope ID 02  
pH-Meter Calimatic  
Thermomixer Compact  
Spectrophotometer ND-1000 
Thermostated hot-block 5320  
Megafuge 1.0R 
Microcentrifuge 
Chemiluminescence Chemi Smart 
7500 Real Time PCR system 
Forma Scientific 
Heraeus 
Brand 
Zeiss 
LHD Labortechnik 
Eppendorf 
PEQLab 
Eppendorf 
Heraeus 
Heraeus 
Vilber Lourmat 
Applied Biosystems 
Water bath  Kotterman 
 
2.2 Cellular biological methods 
2.2.1 Cell culture 
All cells were cultured in a cell culture incubator at 37 °C with 5 % CO2. Suspension 
cell culture, cells were maintained by replacement of medium every two to three days 
to keep a cell density between 1 × 105 and 4 × 105 cells/ml. Adherent cells were 
washed once with PBS and suspended with 5 ml trypsin. Then cells were transferred 
into a new labeled flask containing pre-warmed medium and diluted 1:5 or 1:6. Cells 
were counted using a Neubauer cell counting chamber. Dead cells were distinguished 
by trypan blue staining. 
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2.2.2 Storage of eukaryotic cell lines 
Cell freezing: 
Cells were centrifuged at 1500 rpm for 5 min at 4 °C and resuspended in fresh 
medium (1-2 × 106 cells/ml) supplemented with 20 % FBS and 10 % DMSO. Next, 
cells were transferred into cryo-tubes and stored in a -80 °C refrigerator for short term 
or in liquid nitrogen (-196 °C) for long term storage. 
 
Cell thawing: 
To avoid the toxic effects of high DMSO concentration, cells were transferred into a 
15 ml falcon tube with 10 ml fresh pre-warmed medium directly after thawing in 37 
°C water bath. After centrifugation at 1500 rpm for 5 min at 4 °C, the supernatant was 
discarded and cells were resuspended in 10 ml of fresh pre-warmed medium for 
further culture. 
2.2.3 Apoptotic cell death analysis 
Apoptotic cell death was analyzed by propidium iodide (PI) staining and flow 
cytometry according to the protocol of Nicoletti (Nicoletti et al., 1991). Cells were 
centrifuged at 1500 rpm for 5 min, washed once with PBS, resuspended in 200 μl of 
Nicoletti lysis buffer containing 50 μg/ml PI and stored at 4 °C in dark overnight. 
Specific DNA fragmentation was calculated by the formula: ((experimental DNA 
fragmentation – spontaneous DNA fragmentation) / (100 – spontaneous DNA 
fragmentation)) x 100 %.  
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2.2.4 Cell surface staining 
5 x 105 cells were centrifuged at 1500 rpm for 5 min, washed once with PBS 
(supplemented with 1 % FBS), and incubated with 10 μg/ml of corresponding 
antibodies for 30 min at room temperature (RT). Then cells were washed once with 
PBS (supplemented with 1 % FBS), and incubated with 10 μg/ml FITC-conjugated 
goat anti-mouse antibody for 30 min at RT. Again cells were washed once with PBS 
(supplemented with 1 % FBS), resuspended in 200 μl PBS and finally measured by 
flow cytometry in 200 μl PBS. The following antibodies were used: HS101 
(TRAIL-R1), HS201 (TRAIL-R2), HS301 (TRAIL-R3), HS402 (TRAIL-R4) (Alexis, 
San Diego), FITC-conjugated anti-mouse IgG1 (USBio) and FITC-conjugated goat 
anti-mouse antibody (Alexis). 
 
2.2.5 Cell fixation 
For HTLV-1-associated ATL cell lines (SP, MT-2 and MT-4) it is indispensable to fix 
cells before taking them out of the S3 lab. Infected cells were washed once with PBS, 
added to freshly thawed or freshly prepared 2-4 % PFA (Paraformaldehyde)/PBS for 
90 min at 4 °C. Then cells were washed once with PBS and transferred to a fresh tube 
for further experiments. 
 
2.3 Molecular biological methods 
2.3.1 Total RNA isolation 
Total RNA was isolated by using RNeasy Mini Kit (50) (Qiagen). 5 x 105 cells were 
collected by centrifuging at 1500 rpm for 5 min and homogenized with 350 μl lysis 
buffer RLT (with 10 μl/ml β-ME). 350 μl 70 % Ethanol was added into homogenized 
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lysates and mixed. After being transferred to RNeasy spin columns, samples were 
centrifuged 15 s at 10,000 rpm and flow-through was discarded. 700 μl wash buffer 
RW1 was pipetted onto spin columns and samples were centrifuged as above. Next, 
spin columns were placed in new collection tubes. Samples were centrifuged twice 
with 500 μl wash buffer RPE at 10,000 rpm for 15 s and at full speed for 2 min. 
Finally spin columns were transferred to new 1.5 ml collection tubes and RNA was 
eluted with 30 μl DEPC-treated water by centrifugation for 1 min at 10,000 rpm. 
Total RNA concentration was measured by using a spectrophotometer (PEQLab). The 
RNA samples were stored at -80 °C. 
 
2.3.2 Reverse transcription reaction (RT) 
Reverse transcription reaction was carried out by using RT PCR Kit (Applied 
Biosystems). The reaction system was prepared as follows:  
 
Reagents 
RNA 
50 mM MgCl2  
10 x PCR buffer 
100 mM Oligo-dT  
RNase inhibitor 
dNTP mixture (10 mM each) 
DEPC-treated water 
Amount 
1 μg 
4 μl 
2 μl 
1 μl 
1 μl 
1 μl 
Filled up to 19 μl 
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The mixture was heated at 65 °C for 3 min and cooled at 4 °C for 5 min. After 
addition of 1 μl of Reverse Transcriptase, the mixture was placed in a Thermocycler 
(Bio-Rad) for the following steps:  
 
42 °C 
95 °C 
4 °C 
45 min 
5 min 
5 min 
 
cDNA was stored at -20 °C. For Polymerase Chain Reaction, 4.4 μl of cDNA was 
added to a total volume of 25 μl PCR mixture. 
 
2.3.3 Polymerase Chain Reaction (PCR) 
The purpose of a PCR is to make a huge number of gene copies. The PCR mixture 
was prepared as follows:  
 
Reagents 
10 x PCR buffer 
dNTP mixture ( 10 mM each) 
Forward primer 
Reverse primer 
RT product 
Taq DNA polymerase 
H2O 
Volume (μl) 
5 μl 
1 μl 
1 μl  
1 μl 
20 ng 
1 μl 
Filled up to 50 μl 
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The mixture was placed in a Thermocycler (Bio-rad) for the following steps:  
 
Steps 
Start 
Denaturation 
Annealing 
Extension 
Termination 
Time 
5 min 
1 min 
1 min 
2 min 
10 min 
Temperature 
95 °C 
95 °C          
60 °C     
72 °C  
72 °C 
 
Three major steps (denaturation, annealing and extension) were repeated for 25 to 30 
cycles. The size of the PCR products was verified by a 1.5 % agarose gel containing 
ethidium bromide.  
 
2.3.4 Quantitative real-time PCR 
TaqMan PCR 
Reagents for TaqMan PCR were all purchased from Eurogentec. The reaction system 
was prepared as follows:  
 
PCR-Mix (1ml): 
Reagents 
10 x PCR buffer  
50 mM MgCl2 
dNTP mixture ( 5 mM each with dUTP) 
HGS Polymerase 
Uracil-N-Glycolase 
H2O 
Volume (μl) 
200  
400  
160  
10  
20  
210 
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Reaction Mixture (μl): 
 
Forward Primer 
Reverse Primer 
Probe 
DNA template 
PCR-Mix 
H2O  
c-FLIPL/18S rRNA 
0.88  
5.3 
3.5 
4.4 
43.8 
29.8 
c-FLIPS 
5.3 
15.8 
3.5 
4.4 
43.8 
14.9 
MDM2 
5.3 
0.88 
3.5 
4.4 
43.8 
29.8 
p53 
15.8 
15.8 
3.5 
4.4 
43.8 
4.4 
Reaction mixture was pipetted into 96-well plate (Applied Biosystems) with 25 μl 
each well. Fluorescence signals of samples were measured and analyzed by 7500 Real 
Time PCR system (Applied Biosystems). Relative mRNA was calculated by the 
following formula: 2-△Ct (△Ct= experimental Ct – control Ct) and the standard 
deviations were calculated from the triplicates. 
 
SYBR Green PCR 
Reagents for SYBR Green PCR were all purchased from Eurogentec. The reaction 
system was prepared as follows:  
 
PCR-Mix (1ml): 
Reagents 
10 x PCR buffer  
SYBR Green 1:2000 
50 mM MgCl2 
dNTP mixture ( 5 mM each with dUTP) 
HGS Polymerase 
Uracil-N-Glycolase 
H2O 
Volume (μl) 
200  
60 
120 
80  
10  
20  
510 
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Reaction Mixture (μl): 
 
Forward Primer 
Reverse Primer 
DNA template 
PCR-Mix 
H2O  
TRAIL-R2 
5.3 
5.3 
4.4 
43.8 
28.9 
GAPDH 
15.8 
0.88 
4.4 
43.8 
23.8 
 
Data measurement and analysis are described previously (see TaqMan PCR).  
 
2.3.5 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method to separate mixed double stranded DNA 
fragments according to their differences in length. 1.5 % agarose gels are made by 
agarose and 0.5 x TBE buffer. After agarose suspension was boiled and cooled down 
to about 50 °C, ethidium bromide was added to a final concentration of 0.5 μg/ml. 20 
μl PCR products with 4 μl 6 x loading buffer were loaded on the agarose gel. The 
PCR products were electrophoresed at 100 V for 30 min. The ethidium bromide 
stained DNA fragments were visualized by UV illumination (366 nm).  
 
2.3.6 Extraction and purification of DNA from agarose gels 
DNA was extracted and purified by using QIAquick Gel Extraction Kit (Qiagen). All 
centrifugation steps were carried out at 13000 rpm at RT. DNA fragments were cut 
from the agarose gel with a clean and sharp scalpel. After weighing in a clean 
eppendorf tube, the gel slice was added to 3 times volume of Buffer QG (100 μl for 
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100 mg). When dissolved completely at 50 °C. 1 gel volume of isopropanol was 
added and mixed. Then the sample was applied to a QIAquick column and 
centrifuged for 1 min. To remove all traces of agarose, Buffer QG was added to the 
sample and the column was centrifuged for 1 min. After washing once with 0.75 ml of 
Buffer PE and centrifugation for 1 min, the column was again centrifuged for 1 min to 
remove residual ethanol. Then the column was put into a new 1.5 ml microcentrifuge 
tube and DNA fragments were collected after elution with buffer EB or water by 
centrifugation for 1 min. DNA was stored at -20 °C for further experiments.   
 
2.3.7 Measurement of RNA and DNA concentration 
RNA or DNA concentration was measured by using the spectrophotometer ND-1000 
(PEQLab) and the software NanoDrop 1000 3.7.1. 
 
2.3.8 Preparation of protein lysates for Western blot 
Cells were collected by centrifuging at 1500 rpm for 5 min at 4 °C. Supernatant was 
sucked off and pellets were washed once with PBS at 2000 rpm for 5 min at 4 °C. 
Cells were resuspended with RIPA buffer (200 μl RIPA for 1 x 107 cells) and 
incubated on ice for 20 min. After cells were centrifuged at 13000 rpm for 30 min at 4 
°C, supernatants were transferred into new eppendorf tubes. After addition of loading 
buffer, protein lysates were denatured at 95 °C for 10 min.  
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2.3.9 SDS PAGE 
Bio-Rad 1.5 mm spacer plates, 10-well combs and gel apparatus were cleaned and 
assembled. Laemmli resolving gel and stacking gel were prepared according to the 
table below:   
 
Laemmli resolving gel  
1.5 M Tris-Base + 0.4 % SDS, pH 8.8 (ml) 
H2O (ml) 
30 % Acrylamide mix (ml) 
10 % APS (μl) 
TEMED (μl) 
 
Laemmli stacking gel  
1.5 M Tris-Base + 0.4 % SDS, pH 6.8 (ml) 
H2O (ml) 
30 % Acrylamide mix (ml) 
10 % APS (μl) 
TEMED (μl) 
13 % 
4 
5.1 
6.9 
100 
10 
 
 
2.5 
5.9 
1.6 
100 
10 
10 % 
4 
6.7 
5.3 
100 
10 
 
 
 
 
 
7.5 % 
4 
8 
4 
100 
10 
 
The mixed solution for Laemmli resolving gel was loaded and covered with 70 % 
ethanol. When the gel was polymerized (20 to 30 min), the layer of ethanol was 
discarded. Then the mixture of Laemmli stacking gel was syringed onto the separating 
gel and an appropriate comb was inserted immediately. After the stacking gel was 
polymerized (10 min), denatured protein lysates (95 °C for 10 min) were loaded. SDS 
PAGE was run about 1 hour at 35 mA per gel until the blue dye front reached the 
bottom of the gel. 
 
added before use  
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2.3.10 Western blot 
When SDS PAGE running was finished, resolving gel was kept for blotting. Each 
resolving gel was stacked between whatman papers for transfer of proteins onto the 
nitrocellulose membrane in transfer buffer for 2 hours at a constant current of 60 mA. 
After transfer, the nitrocellulose membrane was incubated for 1 h in 5 % BSA. After 
BSA blocking, first antibody was added to the nitrocellulose membrane at 4 °C 
overnight. Before incubation with second antibody for 1 hour, the membrane was 
washed three times (5 min each time) with washing buffer. When second antibody 
incubation was finished, the membrane was washed again three times. For Western 
blot developing, the ECL kit (PerkinElmer Life Sciences) was used according to the 
manufacture’s introduction. A mixture of solution A and B (1:1) was added to the 
membrane for 1 min and the membrane signal was detected and analyzed by using 
Chemiluminescence Chemi Smart (Vilber Lourmat).
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3. RESULTS 
3.1 Wogonin sensitizes HTLV-1-associated ATL cells to  
TRAIL-induced apoptosis  
3.1.1 HTLV-1-associated ATL cells are resistant to TRAIL-induced 
apoptosis 
TRAIL is a promising candidate for cancer therapy. However, approximately 50 % of 
tumors show resistance to TRAIL-induced apoptosis including HTLV-1-associated 
ATL (LeBlanc et al., 2003; Matsuda et al., 2005; Ishii et al., 2007; Bleumink et al., 
2010). To systematically investigate the mechanism by which HTLV-1-associated 
ATL cells escape TRAIL-mediated apoptosis, three HTLV-1-associated ATL cell 
lines, SP, MT-2 and MT-4 were examined. Cells were treated with different 
concentrations of recombinant TRAIL for 24 h and apoptotic cell death was 
determined by DNA fragmentation according to the method of Nicoletti ((Nicoletti et 
al., 1991). Apoptotic cell death of the HTLV-1-associated ATL cell lines was 
compared to a control leukemic cell line, Jurkat 16, which is not HTLV-1-infected 
and is sensitive towards TRAIL-induced apoptosis. After treatment with TRAIL (10 
ng/ml), 80 % of Jurkat 16 cells underwent apoptosis (Fig. 3.1A), whereas even 100 
ng/ml of TRAIL had no effect on HTLV-1-associated ATL cells (Fig. 3.1B). This 
demonstrates that HTLV-1-associated ATL cell lines are resistant towards 
TRAIL-induced apoptosis.  
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Figure 3.1 HTLV-1-associated ATL cell lines are resistant towards TRAIL-induced 
apoptosis.  
(A) The non-infected leukemic cell line Jurkat 16 and (B) the HTLV-1-associated ATL cell lines 
SP, MT-2 and MT-4 were incubated with different concentrations of TRAIL for 24 h. Apoptotic 
cell death was determined by the Nicoletti assay. Means ± SD are shown. The results shown are 
representative of three independent experiments. 
 
3.1.2 Sensitization of HTLV-1-associated ATL cells towards 
TRAIL-induced apoptosis by Wogonin 
We have previously shown that Wogonin, derived from the Traditional Chinese 
Medicine (TCM) plant Huang-Qin (Scutellaria baicalensis Georgi), can sensitize the 
leukemic cell lines (CEM and Jurkat) and primary acute myeloid leukemia cells 
towards TRAIL-induced apoptosis. Importantly, Wogonin does not affect the viability 
of peripheral blood T cells derived from healthy donors (Fas et al., 2006). To study 
whether Wogonin can sensitize HTLV-1-associated ATL cells to TRAIL-induced 
apoptosis, SP, MT-2 and MT-4 cells were treated with TRAIL alone or in combination 
with Wogonin (Fig. 3.2). Apoptotic cell death was examined by DNA fragmentation. 
The experiment showed that about 5 % of the cells underwent apoptosis after 
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treatment for 24 h with 10-100 ng/ml of TRAIL. Treatment with 50 μM of Wogonin 
led to apoptosis induction of 5-20 %. However, a combination of Wogonin and 
TRAIL resulted in 30-80 % of apoptotic cell death. Thus, Wogonin can sensitize 
HTLV-1-associated ATL cells to TRAIL-induced apoptosis. 
 
 
Figure 3.2 Wogonin sensitizes HTLV-1-associated ATL cell lines towards TRAIL-induced 
apoptosis.  
SP, MT-2 and MT-4 cells were treated either with different concentrations of TRAIL or Wogonin 
(50 μM) alone or in combination for 24 h. Apoptotic cell death was determined by Nicoletti and 
represented as specific DNA fragmentation. Means ± SD are shown. The results shown are 
representative of three independent experiments. 
 
3.1.3 Wogonin enhances TRAIL-induced cleavage of caspase, Bid 
and PARP   
Pro-caspase-8 cleavage and activation is the first event after death receptor triggering. 
Activation of pro-caspase-8 is followed by processing and activation of downstream 
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effector pro-caspase-3 and, consequently, of PARP. Additionally, cleavage of Bid by 
caspase-8 leads to crosslinking of the extrinsic with the intrinsic apoptosis pathway. 
To confirm that sensitization towards TRAIL-mediated apoptosis by Wogonin is 
triggered through the death receptor, cleavage of pro-caspase-8 and Bid was analyzed. 
The HTLV-1-associated ATL cell lines SP, MT-2 and MT-4 were treated for 24 h with 
TRAIL (50 ng/ml) or Wogonin (50 μM) alone or in combination. As shown in Fig. 3.3, 
Wogonin enhanced TRAIL-induced cleavage of pro-caspase-8 and Bid, leading to 
enhanced caspase-3 activation in all three HTLV-1-associated ATL cell lines. These 
findings demonstrate that Wogonin can enhance TRAIL-induced apoptosis by 
promoting caspase-8 activation and Bid cleavage in HTLV-1- associated ATL cells. 
 
 
Figure 3.3 Wogonin enhances TRAIL-induced cleavage of caspase, Bid and PARP.  
SP, MT-2 and MT-4 cells were treated with TRAIL (50 ng/ml) or Wogonin (50 μM) alone or in 
combination for 24 h. Processing of pro-caspases, Bid and PARP was analyzed by Western blot. 
The expression levels of Tubulin and ERK1 served as controls for equal protein loading. The 
results shown are representative of three independent experiments. 
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3.1.4 Wogonin does not sensitize TRAIL-induced apoptosis in 
non-malignant T cells 
To test whether Wogonin and TRAIL can induce cell death in non-malignant T cells, the 
effect of Wogonin and TRAIL on peripheral blood T lymphocytes was analyzed. Freshly 
isolated peripheral blood T cells from healthy donors were incubated with TRAIL (50 
ng/ml) or Wogonin (50 μM) alone or in combination for 24 and 48 h. Cells were 
harvested and apoptotic cell death was examined by specific DNA fragmentation. As 
shown in Fig. 3.4, only 0-2% of healthy blood T cells underwent apoptosis when treated 
with TRAIL or Wogonin alone, or in combination for 24 h. Additionally, less than 10 % of 
healthy blood T cells underwent apoptosis after treatment of TRAIL and Wogonin in 
combination for 48 h (Fig. 3.4). These data show that Wogonin has almost no effect on 
TRAIL-induced apoptosis in non-malignant T cells. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Wogonin does not sensitize TRAIL-induced apoptosis in non-malignant T cells  
Freshly isolated peripheral blood T cells from healthy donors were treated with TRAIL (50 ng/ml) 
or Wogonin (50 μM) alone or in combination for 24 or 48 h. Apoptotic cell death was 
examined by specific DNA fragmentation. The data shown are representative of two 
independent experiments. 
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3.2 Molecular mechanisms of Wogonin-mediated sensitization of  
TRAIL-induced apoptosis  
3.2.1 Wogonin down-regulates c-FLIP expression 
3.2.1.1 Wogonin inhibits c-FLIP protein expression  
c-FLIP is a key inhibitor of the death receptor-mediated apoptotic signalling cascade. 
Our previous study has shown that HTLV-1-associated ATL cells express significantly 
higher c-FLIP protein levels than non-infected leukemic cells and over-expression of 
c-FLIP is responsible for resistance to receptor-mediated apoptosis, which was 
confirmed by knockdown of c-FLIP (Krueger et al., 2006). We have also shown that 
inhibition of c-FLIP expression by the natural compound Rocaglamide breaks TRAIL 
resistance in HTLV-1-associated ATL cells (Bleumink et al., 2010). Additionally, it 
was reported that down-regulation of c-FLIP leads to sensitization of TRAIL-induced 
apoptosis in acute myeloid leukemia (AML) (Suh et al., 2003) or HTLV-1-associated 
ATL cells (Okamoto et al., 2006). Therefore, the effect of Wogonin on c-FLIP protein 
expression was analyzed. SP, MT-2 and MT-4 cells were treated with Wogonin 
(50 μM or 100 μM) for 8 h and c-FLIP protein level was analyzed by Western blot. 
As shown in Fig. 3.5A, c-FLIPL and c-FLIPS protein levels were significantly 
down-regulated in all three cell lines upon Wogonin treatment. Kinetic analysis of 
c-FLIP protein levels in SP cells showed that c-FLIPL and c-FLIPS protein expression 
was decreased after 3 h of Wogonin treatment (50 μM) and completely inhibited after 
24 h of treatment (Fig. 3.5B). These results demonstrate that the inhibition of c-FLIP 
expression is one possible mechanism by which Wogonin sensitizes TRAIL-induced 
apoptosis. 
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Figure 3.5 Wogonin suppresses the expression of the anti-apoptotic protein c-FLIP 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h or (B) SP 
cells were treated with Wogonin (50 μM) for indicated time periods (1.5, 3, 6, 9 and 24 h). Cells 
were lysed and c-FLIP protein levels were analyzed by Western blot. Tubulin expression served as 
a control for equal protein loading. Data shown are representative of three independent 
experiments. 
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3.2.1.2 HTLV-1-associated ATL cells express higher c-FLIP mRNA            
levels than non-infected leukemic cells 
c-FLIP protein levels are increased in HTLV-1-associated ATL cells compared to 
non-infected leukemic cells (Krueger et al., 2006), but it is not clear whether the 
c-FLIP mRNA levels are also elevated in HTLV-1-associated ATL cells. Therefore, 
the c-FLIP mRNA levels were measured by TaqMan real time PCR in different 
HTLV-1-associated ATL cells and control Jurkat 16 cells. As shown in Fig. 3.6, all 
three HTLV-1-associated ATL cell lines expressed greatly increased mRNA levels of 
both c-FLIPL and c-FLIPS compared to Jurkat 16 cells. These findings show that 
HTLV-1-associated ATL cell lines express 4-9 fold higher levels of c-FLIP mRNA 
than non-infected leukemic cell line Jurkat 16. 
 
 
 
 
 
 
 
 
Figure 3.6 HTLV-1-associated ATL cells express increased amounts of c-FLIP mRNA.  
c-FLIP absolute mRNA levels in HTLV-1-associated ATL cell lines SP, MT-2, MT-4 and 
non-infected leukemic cell line Jurkat 16 were analyzed by TaqMan real time PCR described in 
materials and methods. The data are representative of three independent experiments. 
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3.2.1.3 Wogonin suppresses c-FLIP expression at the mRNA level 
Recently, our group found that Wogonin is a potent inhibitor of CDK9 
(cyclin-dependent kinase 9) which plays a major role in regulation of transcription. 
Additionally, Wogonin induces apoptosis by suppressing transcription of Mcl-1, an 
anti-apoptotic protein with a short half life (Polier et al., unpublished data). It has 
been previously reported that c-FLIP isoforms are short-lived proteins as well and 
their expression can be easily attenuated by using protein or RNA synthesis inhibitors 
(Fulda et al., 2000; Hernandez et al., 2001). We showed above that 
HTLV-1-associated ATL cells express elevated c-FLIP mRNA levels (Fig. 3.6). 
Therefore, we further investigated whether Wogonin down-regulates c-FLIP mRNA 
levels in HTLV-1-associated ATL cells. Three HTLV-1-associated ATL cell lines SP, 
MT-2 and MT-4 were treated with Wogonin (50 μM) for different time periods and 
the relative mRNA expression levels were measured by TaqMan real time PCR. As 
shown in Fig. 3.7, c-FLIPL and c-FLIPS mRNA levels started to decrease after 3 h of 
treatment with Wogonin (50 μM). These data demonstrate that Wogonin suppresses 
c-FLIP expression at the transcriptional level. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Wogonin suppresses c-FLIP mRNA expression  
SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM) for 0, 3, 6 and 9 h. The relative 
c-FLIP mRNA expression level was measured by TaqMan real time PCR using 18S rRNA as a 
control. The data are representative of two independent experiments. 
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3.2.2 Wogonin up-regulates TRAIL-R2 expression 
3.2.2.1 Wogonin increases TRAIL-R2 protein expression levels 
Previous studies have shown that certain drugs can sensitize resistant cancer cells 
towards TRAIL-mediated apoptosis by up-regulating TRAIL death receptor 
expression (Kim et al., 2004; Shiraishi et al., 2005; Yoshida et al., 2005; Carter et al., 
2008; Kim et al., 2010). To examine whether Wogonin could affect the expression of 
TRAIL receptors, SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 
μM) for 16 h and the protein levels of different TRAIL receptors were analyzed by 
Western blot. Up-regulation of TRAIL-R2 was observed in all three 
HTLV-1-associated ATL cell lines after treatment with Wogonin (Fig. 3.8A). Kinetic 
analysis of TRAIL death receptor expression upon treatment with Wogonin (50 μM) 
for 1.5 h to 24 h showed that TRAIL-R2 protein levels were increased by Wogonin 
after 9 h of treatment (Fig. 3.8B). The expression of other TRAIL receptors 
experienced no changes with Wogonin treatment. These experiments demonstrate that 
Wogonin may sensitize TRAIL-induced apoptosis through up-regulation of 
TRAIL-R2 expression. 
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Figure 3.8 Wogonin up-regulates TRAIL-R2 protein expression in HTLV-1-associated ATL 
cells 
(A) HTLV-1-associated ATL cell lines SP, MT-2 and MT-4 cells were treated with Wogonin (50 
μM or 100 μM) for 16 h or (B) with 50 μM of Wogonin for different time periods (1.5, 3, 6, 9, 12 
and 24 h). Cells were lysed and TRAIL receptor protein level was analyzed by Western blot. 
Tubulin expression served as a control for equal protein loading. The results shown are 
representative of two independent experiments. 
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3.2.2.2 Wogonin up-regulates TRAIL-R2 surface expression  
In addition to increased TRAIL-R2 protein expression level, TRAIL death receptor 
surface expression was also measured in HTLV-1-associated ATL cells treated with 
Wogonin (50 μM) for 16 h. As shown in Fig. 3.9, TRAIL-R2 surface expression was 
increased by Wogonin treatment in all three cell lines, while TRAIL-R1 surface 
expression was not significantly enhanced. This result is consistent with the total 
protein expression levels of TRAIL death receptors showing that only TRAIL-R2 but 
not TRAIL-R1 expression level is elevated by Wogonin treatment (Fig. 3.8). These 
findings imply that Wogonin may sensitize TRAIL-induced apoptosis through 
up-regulation of TRAIL-R2 surface expression. 
 
Figure 3.9 Wogonin up-regulates TRAIL-R2 surface expression in HTLV-1-associated ATL 
cells 
SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM) for 16 h. Surface expression of 
TRAIL death receptor TRAIL-R1 and TRAIL-R2 was analyzed by FACS with HS101 (TRAIL-R1) 
and HS201 (TRAIL-R2) or an IgG1 isotype control antibody. The data are representative of two 
independent experiments. 
No Wogonin
50 μM Wogonin
Isotype control
10 1 10 2 10 3 10 4 10 5 
FITC-A 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 TRAIL-R2
16 h
FITC-A 
10 1 10 2 10 3 10 4 10 5 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 TRAIL-R1
16 h
SP SP
MT-2
10 0 10 1 10 2 10 3 
FITC-A 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 TRAIL-R1
16 h
10 4
MT-2
10 0 10 1 10 2 10 3 
FITC-A 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 
10 4
TRAI-R2
16 h
MT-4
10 0 10 1 10 2 10 3 
FITC-A 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 TRAIL-R1
16 h
10 4
MT-4
10 0 10 1 10 2 10 3 
FITC-A 
0 
20 
40 
60 
80 
100 
%
 o
f M
ax
 
10 4
TRAI-R2
16 h
%
 o
f M
ax
 
%
 o
f M
ax
 
%
 o
f M
ax
 
%
 o
f M
ax
 
%
 o
f M
ax
 
%
 o
f M
ax
 
 
 
Results                
 75
3.2.2.3 Wogonin elevates TRAIL-R2 expression at the mRNA level 
To investigate how Wogonin enhances TRAIL-R2 expression, the effect of Wogonin 
on TRAIL-R2 mRNA expression levels in SP, MT-2 and MT-4 cells was analyzed. All 
three cell lines were treated with Wogonin (50 μM) for different time periods from 1.5 
h to 24 h. Although the TRAIL-R2 mRNA expression level was slightly 
down-regulated (about 20%-30%) at early time points (0-6 h), it was consistently 
up-regulated (1.5 to 2.5 fold) after 6 h of treatment (Fig. 3.10). These data 
demonstrate that Wogonin increases TRAIL-R2 expression at the transcriptional level. 
 
 
 
 
 
 
 
 
 
Figure 3.10 Wogonin increases TRAIL-R2 expression at the mRNA level 
SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM) for 0, 1.5, 3, 6, 9, 12 and 24 h. The 
relative TRAIL-R2 mRNA expression level was measured by SYBR Green real time PCR using 
GAPDH for normalization. Means ± SD are shown. The data are representative of two 
independent experiments. 
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3.2.2.4 Increase of TRAIL-R2 mRNA level by Wogonin correlates          
with increased p53 protein level  
TRAIL-R2 mRNA has a short half-life of about 4 h (Kandasamy et al., 2008). Since 
Wogonin can target transcription (Polier et al., unpublished data), this may explain the 
result in Fig. 3.10 that Wogonin suppresses TRAIL-R2 mRNA expression at early 
treatment. However, the mechanism by which Wogonin increased TRAIL-R2 mRNA 
level at later points is not clear.  
p53 has been shown to transactivate the TRAIL-R2 gene through an intronic 
sequence-specific DNA-binding site (+ 0.25 Kb downstream of the ATG) (Takimoto 
et al., 2000). It was reported that the natural compound triptolide sensitizes AML cells 
to TRAIL-induced apoptosis via p53-mediated increase of TRAIL-R2 (Carter et al., 
2008). Therefore, we further investigated whether Wogonin-mediated up-regulation of 
TRAIL-R2 is also regulated by a p53-dependent mechanism. To investigate this 
possibility, the effect of Wogonin on p53 protein levels in HTLV-1-associated ATL 
cells was analyzed. SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 
100 μM) and the protein levels of p53 were analyzed by Western blot. The experiment 
showed that Wogonin up-regulated p53 expression in a dose- and time-dependent 
manner (Fig. 3.11). These results suggest that Wogonin may up-regulate TRAIL-R2 
protein expression by increasing the p53 protein level.  
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Figure 3.11 Wogonin increases the protein level of the transcription factor p53 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h or (B) with 
50 μM of Wogonin for different time periods (1.5, 3, 6, 9 and 24 h). p53 protein level was 
analyzed by Western blot. Tubulin expression served as a control for equal protein loading. The 
data shown are representative of two independent experiments. 
 
3.2.2.5 The Wogonin-mediated up-regulation of the p53 protein level 
is due to decreased MDM2 protein expression 
The p53 protein level is strictly controlled by the negative regulator MDM2. On the 
one hand, MDM2 binds directly to the N-terminal end of p53 to inhibit its function 
(Momand et al., 1992; Oliner et al., 1993). On the other hand, the E3 ubiquitin ligase 
activity of MDM2 targets p53 for ubiquitination and subsequently degradation by the 
26S proteasome (Haupt et al., 1997; Honda et al., 1997). Therefore, the expression 
levels of MDM2 in Wogonin-treated HTLV-1-associated ATL cells were investigated. 
SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h or 
with 50 μM of Wogonin for different time periods (1.5, 3, 6, 9 and 24 h). The MDM2 
protein expression levels were analyzed by Western blot. The experiments showed 
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that Wogonin strongly inhibited MDM2 protein expression (Fig. 3.12A). Kinetic 
analysis showed that MDM2 was rapidly down-regulated already after 1.5 h of 
treatment (Fig. 3.12B). These results suggest that Wogonin-mediated increases in p53 
protein levels may involve a mechanism of MDM2 suppression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Wogonin inhibits MDM2 protein expression 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h or (B) with 
50 μM of Wogonin for various time periods (1.5, 3, 6, 9 and 24 h). The MDM2 protein expression 
level was analyzed by Western blot. Tubulin expression served as a control for equal protein 
loading. The results shown are representative of two independent experiments. 
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3.2.2.6 p53 and MDM2 expression is suppressed by Wogonin at the 
mRNA level 
We have recently shown that Wogonin inhibits CDK9 activity and suppresses gene 
expression at the transcriptional level (Polier et al., unpublished data). In order to 
investigate the effect of Wogonin on the mRNA level of p53 and MDM2, 
HTLV-1-associated ATL cell lines SP, MT-2 and MT-4 were treated with 50 μM of 
Wogonin for different time periods (3, 6 and 9 h) and the mRNA expression levels of 
p53 and MDM2 were measured by TaqMan real time PCR. As shown, Wogonin 
inhibited both p53 and MDM2 mRNA expression in all three cell lines (Fig. 3.13). 
These experiments are consistent with our previous finding that Wogonin inhibits 
mRNA expression. 
 
Figure 3.13 Wogonin suppresses p53 and MDM2 mRNA expression 
SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM) for 0, 3, 6 and 9 h. The relative p53 
and MDM2 mRNA expression level was measured by TaqMan real time PCR, using 18S rRNA as 
a control. Means ± SD are shown. The data are representative of two independent experiments. 
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3.2.2.7 TRAIL-R2 protein expression in p53-deleted cell lines is not 
increased by Wogonin  
In order to further investigate the role of p53 in Wogonin-induced TRAIL-R2 
expression, the effect of Wogonin on TRAIL-R2 protein expression level was 
analyzed in two p53-deleted tumor cell lines PC3 (human prostate cancer cell line) 
and Hep3b (human hepatoma cell line) and in parallel in the control cell line HepG2 
(human hepatoma cell line) which harbour wild-type p53. All three cell lines were 
treated with Wogonin (50 μM) for 8 or 16 h. TRAIL-R1 and TRAIL-R2 protein 
expression was measured by Western blot. As shown in Fig. 3.14, Wogonin did not 
increase the TRAIL-R2 expression in the two p53 deficient cell lines, while it 
significantly enhanced TRAIL-R2 expression levels in the control HepG2 cells. 
Interestingly, TRAIL-R1 protein level was also increased in HepG2 cells by Wogonin 
treatment, whereas no enhancement of TRAIL-R1 expression was observed in PC3 
and Hep3b cells. This result demonstrates that Wogonin-induced up-regulation of 
TRAIL-R2 expression is p53 dependent. 
 
 
 
 
 
 
 
 
Figure 3.14 Wogonin does not increase TRAIL-R2 protein expression in p53-deleted tumor 
cell lines 
Two p53-deleted tumor cell lines PC3 and Hep3b and a p53 wild type tumor cell line HepG2 were 
treated with Wogonin (50 μM) for 8 or 16 h. TRAIL-R1 and TRAIL-R2 protein expression level 
was analyzed by Western blot. Tubulin expression served as a control for equal protein loading. 
The results shown are representative of two independent experiments. 
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3.2.2.8 The protein expression of transcription factors CHOP and 
Sp1 is not influenced by Wogonin        
Besides p53, two other transcription factors, CHOP and Sp1, have been implicated in 
regulating TRAIL-R2 expression. It was shown that the CHOP binding site is 
localized at -270 bp of the TRAIL-R2 promoter and four putative Sp1 binding sites 
are located in the region of the TRAIL-R2 promoter spanning nucleotide -605 to +3 
(Yoshida et al., 2001). Since several publications have reported that certain drugs can 
sensitize cancer cells to TRAIL-mediated apoptosis through CHOP or Sp1-mediated 
up-regulation of TRAIL-R2 (Kim et al., 2004; Shiraishi et al., 2005; Yoshida et al., 
2005; Kim et al., 2010), we asked whether enhancement of TRAIL-R2 expression by 
Wogonin treatment is also mediated by CHOP or Sp1. To answer this question, SP 
and MT-4 cells were treated with Wogonin (50 μM) for different time periods and 
CHOP and Sp1 protein expression were analyzed by Western blot. As seen in Fig. 
3.15, CHOP and Sp1 protein expression were not influenced by Wogonin, suggesting 
that CHOP and Sp1 are not involved in Wogonin-induced TRAIL-R2 up-regulation in 
HTLV-1-associated ATL cells. 
 
Figure 3.15 Protein expression of the transcription factors CHOP and Sp1 is not influenced 
by Wogonin 
SP and MT-4 cells were treated with Wogonin (50 μM) for different time periods (1.5, 3, 6, 9 and 
24 h). CHOP and Sp1 protein expression were analyzed by Western blot. Tubulin expression 
served as a control for equal protein loading. The results shown are representative of two 
independent experiments. 
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3.2.3 Effects of Wogonin on the expression of pro- and anti-apoptotic 
proteins   
3.2.3.1 Comparison of pro- and anti-apoptotic protein expression 
levels in HTLV-1-associated ATL cells and non-infected 
leukemic T cells 
Besides c-FLIP, apoptotic resistance in HTLV-1-associated ATL cells has been partly 
explained by abnormal expression of some other proteins involved in cell death 
pathways. It has been shown that in HTLV-1-associated ATL cells several 
anti-apoptotic proteins are up-regulated, such as Bcl-2 (Bleumink et al., 2010), Bcl-xL 
(Mori et al., 2001; Tsukahara et al., 1999) and IAP family proteins (Kawakami et al., 
1999; Waldele et al., 2006). In order to obtain an overview of misregulated proteins 
which may be involved in apoptotic resistance in HTLV-1-associated ATL cells, 
expression levels of pro- and anti-apoptotic proteins in HTLV-1-associated ATL cells 
and control Jurkat 16 cells were systematically compared (Fig. 3.16). Consistent with 
previous reports (Krueger et al., 2006; Bleumink et al., 2010), c-FLIP, Bcl-xL
 
and 
Bcl-2 expression were shown to be increased in HTLV-1-associated ATL cells. In 
addition, the anti-apoptotic proteins XIAP and Mcl-1 were also found to be 
up-regulated. However, the expression of pro-apoptotic proteins Bad and Bax was 
enhanced as well in HTLV-1-associated ATL cells (Fig. 3.16). 
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Figure 3.16 Comparison of pro- and anti-apoptotic protein expression in HTLV-1- 
associated ATL cells and non-infected leukemic T cells 
Expression of pro- and anti-apoptotic proteins in HTLV-1-associated ATL cells SP, MT-2, MT-4 
and a non-infected leukemic cell line Jurkat 16 cells was analyzed by Western blot. Tubulin levels 
served as a control for equal loading of proteins. The data are representative of two independent 
experiments. 
 
3.2.3.2 Wogonin does not influence XIAP protein expression 
XIAP is a member of the IAPs family and it suppresses apoptosis by inhibiting the 
activity of effector caspases, such as caspase-3, -7 and -9. It has been reported that 
down-regulation of XIAP sensitizes TRAIL- or CD95-induced apoptosis in various 
tumor cells (Kim et al., 2004; Kim et al., 2005; Loeder et al., 2010). We show that 
XIAP expression is increased in HTLV-1-associated ATL cells compared to 
non-infected leukemic Jurkat 16 cells. Therefore, the effect of Wogonin on the protein 
expression of XIAP in HTLV-1-associated ATL cells was further analyzed. SP, MT-2 
and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h and XIAP 
protein expression was analyzed by Western blot. As seen in Fig. 3.17A, Wogonin did 
not influence XIAP protein expression in all three cell lines after 8 h treatment. 
Kinetic analysis showed that a slightly reduced XIAP protein level was observed only 
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after 24 h treatment with Wogonin (Fig. 3.17B). These findings suggest that 
Wogonin-mediated sensitization of TRAIL-induced apoptosis is not mediated through 
down-regulation of XIAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Wogonin does not influence XIAP protein expression 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h and (B) SP 
cells were treated with 50 μM of Wogonin for various time periods (1.5, 3, 6, 9 and 24 h). XIAP 
protein expression level was analyzed by Western blot. Tubulin and ERK1 expression served as a 
control for equal protein loading. The results shown are representative of two independent 
experiments. 
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3.2.3.3 Wogonin inhibits protein expression of Mcl-1 but not other 
Bcl-2 family members 
The Bcl-2 family of proteins is the most important regulator of the intrinsic apoptosis 
pathway. Although both anti- and pro-apoptotic Bcl-2 family proteins are increased in 
HTLV-1-associated ATL cells compared to non-infected leukemic cells (Fig. 3.16), the 
effect of Wogonin on expression of these proteins needs to be investigated. Therefore, 
three HTLV-1-associated ATL cell lines, SP, MT-2 and MT-4, were treated with 
Wogonin (50 μM or 100 μM) for 8 h or SP cells were treated with Wogonin (50 μM) 
for different time periods. The expression of Bcl-2 family proteins was analyzed by 
Western blot. As expected, only the short-lived Mcl-1 protein expression was strongly 
reduced (Fig. 3.18A), which is consistent with our recent fingding that Wogonin 
induces apoptosis in cancer cells by suppression of Mcl-1 expression (Polier et al., 
unpublished data). Kinetic analysis showed that Mcl-1 down-regulation occurred as 
early as after 3 h treatment and persisted until 24 hours (Fig. 3.18B).  
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Figure 3.18 Wogonin inhibits Mcl-1 protein expression 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h or (B) SP 
cells were treated with 50 μM of Wogonin for different time periods (1.5, 3, 6, 9 and 24 h). Bcl-2 
family protein expression was analyzed by Western blot. Tubulin and ERK1 expression served as 
a control for equal protein loading. The results shown are representative of two independent 
experiments. 
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3.2.3.4 Wogonin inhibits mRNA expression of Mcl-1  
To investigate the molecular mechanisms by which Wogonin suppresses Mcl-1 
protein expression, the mRNA expression level of Mcl-1 was examined. SP cells were 
incubated with Wogonin for different time periods and the mRNA expression level of 
Mcl-1 was examined by real-time PCR. As shown in Fig. 3.19, Wogonin suppressed 
Mcl-1 mRNA expression in a time-dependent manner. This result is consistent with 
our previous finding that Wogonin inhibits mRNA expression (Polier et al., 
unpublished data).  
  
 
 
 
 
 
 
Figure 3.19 Wogonin suppresses Mcl-1 mRNA expression 
SP cells were treated with Wogonin (50 μM) for 0, 1.5, 3, 6 and 9 h. The Mcl-1 mRNA expression 
level was measured by TaqMan real time PCR, using 18S rRNA as a control. Means ± SD are 
shown. The data are representative of three independent experiments. 
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3.3 Wogonin sensitizes various cancer cells towards 
TRAIL-induced apoptosis by down-regulation of c-FLIP 
and up-regulation of TRAIL-R2 expression  
To further investigate whether Wogonin sensitizes TRAIL-induced apoptosis in other 
cancer cells, apoptotic cell death was measured in four different types of malignant 
cell lines including the human breast cancer cell line MDA-MB-231, the human 
melanoma cell line SK-MEL-37, the human hepatocellular carcinoma cell line HepG2 
and the human colon cancer cell line HT-29. As shown in Fig. 3.20A, Wogonin 
sensitized TRAIL-induced apoptosis in all cell lines tested. In addition, Wogonin 
down-regulated c-FLIP and up-regulated TRAIL-R2 protein expression level in all 
cell lines tested (Fig. 3.20B). Thus, Wogonin can suppress c-FLIP and enhance 
TRAIL-R2 expression in tumor cells in general and this may account for one of the 
mechanisms of Wogonin-mediated sensitization of TRAIL-induced apoptosis in tumor 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Results                
 89
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Wogonin sensitizes different cancer cell lines towards TRAIL-induced apoptosis  
by down-regulation of c-FLIP but up-regulation of TRAIL-R2 protein expression 
(A) Four different types of cancer cell lines MDA-MB-231, SK-MEL-37, HepG2 and HT-29 were 
treated either with different concentration of TRAIL or Wogonin (50 μM) alone or in combination 
for 24 h. Apoptotic cell death was determined by DNA fragmentation. Means ± SD are shown. (B) 
Four indicated cell lines were treated with Wogonin (50 μM) for 16 h. Cell lysates were analyzed 
by Western blot.  
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3.4 Apigenin and Chrysin sensitize HTLV-1-associated ATL 
cells towards TRAIL-induced apoptosis 
3.4.1 Sensitization of HTLV-1-associated ATL cells towards 
TRAIL-induced apoptosis by Apigenin and Chrysin 
So far, several natural flavones have been reported to have anti-carcinogenic activities. 
However, their modes of function as anti-cancer agents are still largely unknown. To 
investigate whether other flavones besides Wogonin could also sensitize 
TRAIL-induced apoptosis, two naturally occurring anti-tumor flavones, Apigenin and 
Chrysin, were tested. The HTLV-1-associated ATL cell line MT-2 was treated with 50 
μM of Apigenin or Chrysin alone or in combination with different concentrations of 
TRAIL for 24 h (Fig. 3.21A). Both Apigenin and Chrysin were shown to sensitize 
TRAIL-induced apoptosis. The experiments showed that at maximum about 20% of 
the cells underwent apoptosis after treatment with 10-100 ng/ml of TRAIL for 24 h 
and approximately 30-40% of cell death was detected after treatment with 50 μM of 
Apigenin or Chrysin. However, a combination of Apigenin or Chrysin and TRAIL 
resulted in a synergistic increase in apoptosis (about 80%). As shown in Fig. 3.21B, 
treatment with 12.5, 25 or 50 μM of Apigenin or Chrysin restored TRAIL sensitivity 
in a dose-dependent manner. These results demonstrate that Apigenin or Chrysin can 
sensitize HTLV-1-associated ATL cells to TRAIL-induced apoptosis. 
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Figure 3.21 Apigenin and Chrysin sensitize HTLV-1-associated ATL cells towards 
TRAIL-induced apoptosis  
(A) The HTLV-1-associated ATL cell line MT-2 was treated either with different concentration of 
TRAIL or 50 μM of Apigenin/Chrysin alone or in combination for 24 h. (B) MT-2 cells were 
treated with 12.5-50 μM of Apigenin or Chrysin alone, or 50 ng/ml of TRAIL alone or in 
combination for 24 h. Apoptotic cell death was determined by DNA fragmentation. Means ± SD 
are shown. The results shown are representative of two independent experiments. 
 
3.4.2 Apigenin and Chrysin suppress c-FLIP protein expression at 
the transcriptional level  
Further, the mechanisms by which Apigenin and Chrysin sensitize 
HTLV-1-associated ATL cells to TRAIL-induced apoptosis were investigated. As 
shown previously (Fig. 3.5 and Fig. 3.7), Wogonin sensitizes TRAIL-induced 
apoptosis in HTLV-1-associated ATL cells by down-regulation of c-FLIP expression 
at both mRNA and protein levels. Therefore, the effects of Apigenin and Chrysin on 
expression of c-FLIP in HTLV-1-associated ATL cells were tested. MT-2 cells were 
treated with Apigenin or Chrysin (50 μM or 100 μM) for 8 h and c-FLIP protein 
expression was analyzed by Western blot. The results showed that 50 μM of Apigenin 
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and Chrysin strongly suppressed c-FLIPL and c-FLIPS protein expression (Fig. 3.22A). 
In addition, the c-FLIP mRNA level was also remarkably inhibited by Apigenin and 
Chrysin in a time-dependent manner (Fig. 3.22B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Apigenin and Chrysin suppress c-FLIP expression at both mRNA and protein 
level 
(A) The HTLV-1-associated cell line MT-2 was treated with Apigenin or Chrysin (50 μM or 100 
μM) for 8 h. c-FLIP protein expression was measured by Western blot. (B) MT-2 cells were 
treated with Apigenin or Chrysin (50 μM) for 3, 6 and 9 hours. The c-FLIP mRNA expression 
levels were measured by TaqMan real time PCR, using 18S rRNA as a control. Means ± SD are 
shown. The data are representative of two independent experiments. 
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3.4.3 Apigenin and Chrysin up-regulate TRAIL-R2 expression 
As shown previously, Wogonin not only down-regulates c-FLIP expression, but also 
enhances TRAIL-R2 expression, which may be another mechanism by which 
Wogonin sensitizes TRAIL-induced apoptosis. To investigate whether Apigenin or 
Chrysin also influence TRAIL receptor protein expression, MT-2 cells were treated 
with 50 μM of Apigenin or Chrysin for 16 h and the expression level of TRAIL was 
analyzed by Western blot (Fig. 3.23). Similar to Wogonin, both Apigenin and Chrysin 
increased TRAIL-R2 protein expression but not TRAIL-R1 and TRAIL-R4 in MT-2 
cells. However, in contrast to Wogonin, down-regulation of TRAIL-R3 by Apigenin 
(100 μM) and Chrysin (50 μM and 100 μM) was observed.  
 
 
 
 
 
          
 
 
Figure 3.23 The effect of Apigenin and Chrysin on expression of TRAIL receptors 
MT-2 cells were treated with Apigenin or Chrysin (50 μM or 100 μM) for 16 h. Protein expression 
of TRAIL death receptors (R1 and R2) and decoy receptors (R3 and R4) was analyzed by Western 
blot. Tubulin expression served as a control for equal protein loading. The results shown are 
representative of two independent experiments. 
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3.4.3.1 The p53 protein level is elevated by Apigenin and Chrysin  
As shown previously in Fig. 3.10 and 3.11, increased TRAIL-R2 expression by 
Wogonin is mediated by up-regulation of p53. Therefore, the effects of Apigenin and 
Chrysin on p53 protein expression levels were investigated. As seen in Fig. 3.24, 
treatment of MT-2 cells with Apigenin or Chrysin (50 μM or 100 μM) for 8 h led to 
significantly elevated p53 protein levels. This experiment demonstrates that the 
Wogonin analogs Apigenin and Chrysin also up-regulate TRAIL-R2 expression by 
enhancing the level of p53. 
 
 
 
 
 
 
 
Figure 3.24 The effect of Apigenin and Chrysin on expression of p53 
MT-2 cells were treated with Apigenin or Chrysin (50 μM or 100 μM) for 8 h. p53 protein level 
was analyzed by Western blot. Tubulin expression served as a control for equal protein loading. 
The results shown are representative of two independent experiments. 
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3.4.3.2 MDM2 protein expression level is reduced by Apigenin and 
Chrysin 
Since MDM2 is a negative regulator of p53 and its expression can be down-regulated 
by Wogonin, we hypothesized that Apigenin and Chrysin act like Wogonin to 
increase p53 protein level via inhibiting MDM2. Indeed, after treatment of the 
HTLV-1-associated ATL cell line MT-2 with Apigenin or Chrysin (50 μM or 100 μM) 
for 8 h, MDM2 expression was completely suppressed (Fig. 3.25).  
 
 
 
 
 
 
Figure 3.25 The effect of Apigenin and Chrysin on the expression of MDM2 
MT-2 cells were treated with Apigenin or Chrysin (50 μM or 100 μM) for 8 h. MDM2 protein 
expression was analyzed by Western blot. Tubulin expression served as a control for equal protein 
loading. The results shown are representative of two independent experiments. 
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3.4.4 Apigenin and Chrysin inhibit Mcl-1 expression in 
HTLV-1-associated ATL cells     
Recently our group has found that Wogonin, Apigenin and Chrysin induce apoptosis 
in cancer cells by suppression of Mcl-1 expression (Polier et al., unpublished data). 
Therefore, the effect of Apigenin and Chrysin on Mcl-1 expression in 
HTLV-1-associated ATL cells was investigated. MT-2 cells were treated with 
Apigenin and Chrysin for 8 h and the expression levels of the major anti- and 
pro-apoptotic proteins involved in the mitochondrial pathway were analyzed by 
Western blot. Consistent with our findings for Wogonin, only Mcl-1 but not other 
proteins were down-regulated by Apigenin and Chrysin. Even 50 μM of each 
compound remarkably inhibited Mcl-1 protein expression (Fig. 3.26).  
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Apigenin and Chrysin inhibit Mcl-1 expression 
MT-2 cells were treated with Apigenin or Chrysin (50 μM or 100 μM) for 8 h. Protein expression 
of anti- and pro-apoptotic proteins of the mitochondrial pathway was analyzed by Western blot. 
Tubulin expression served as a control for equal protein loading. The results shown are 
representative of two independent experiments. 
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3.5 Wogonin, Apigenin and Chrysin do not significantly 
suppress Tax protein expression 
Several anti-apoptotic proteins are up-regulated by Tax-mediated NF-κB activation, 
such as Bcl-xL (Mori et al., 2001; Tsukahara et al., 1999), IAP family proteins 
(Kawakami et al., 1999; Waldele et al., 2006) and c-FLIP (Micheau et al., 2001; 
Kreuz et al., 2001). In addition, Tax is able to prevent Bax relocation to mitochondria 
(Trevisan et al., 2006). Therefore, we asked whether Wogonin, Apigenin and Chrysin 
can suppress Tax protein expression leading to down-regulation of anti-apoptotic 
protein expression and sensitization of TRAIL-induced apoptosis in 
HTLV-1-associated ATL cells. Thus, the effects of Wogonin, Apigenin and Chrysin 
on Tax expression were analyzed. As seen in Fig. 3.27A, SP, MT-2 and MT-4 cells 
were treated with Wogonin for 8 h. The protein expression of Tax was not influenced 
in these three cell lines except that the Tax protein level was marginally reduced in SP 
cells with 100 μM of Wogonin treatment for 8 h. Kinetic analysis of Tax protein 
expression in SP cells showed that Tax protein expression was slightly decreased only 
after 24 h treatment with Wogonin (50 μM) (Fig. 3.27B). Moreover, Tax expression 
was analyzed after Apigenin and Chrysin treatment for 10 h in MT-2 cells. As shown 
in Fig. 3.27C, Apigenin and Chrysin did not influence Tax protein expression in 
MT-2 cells. These results demonstrate that Wogonin, Apigenin and Chrysin do not 
significantly suppress Tax protein expression in HTLV-1-associated ATL cells. 
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Figure 3.27 Wogonin, Apigenin and Chrysin do not significantly suppress Tax protein 
expression 
(A) SP, MT-2 and MT-4 cells were treated with Wogonin (50 μM or 100 μM) for 8 h, (B) SP cells 
were treated with Wogonin (50 μM) for different time periods (1.5, 3, 6, 9 and 24 h), or (C) MT-2 
cells were treated with Apigenin or Chrysin (50 μM or 100 μM) for 10 h. Cells were lysed and Tax 
protein levels were analyzed by Western blot with antibodies against Tax. Tubulin expression 
served as a control for equal protein loading. Data shown are representative of two independent 
experiments. 
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4. DISCUSSION 
4.1 Sensitization of HTLV-1-associated ATL cells to 
TRAIL-induced apoptosis by Wogonin 
TRAIL, considered to be a promising anti-cancer agent, is selectively cytotoxic to 
tumor cells but not to non-malignant cells (Walczak et al., 1999; Bruix et al., 2004; 
Abdulghani and El-Deiry; 2010). However, various tumors show resistance to 
TRAIL-induced apoptosis (LeBlanc et al., 2003; Pan et al., 2007), e.g., prostate 
cancer (Kasman et al., 2006), colon cancer (Ishii et al., 2007) and HTLV-1-associated 
ATL (Matsuda et al., 2005; Bleumink et al., 2010). Here it has been demonstrated that 
HTLV-1-associated ATL cells are resistant towards TRAIL-induced apoptosis (Fig. 
3.1).  
Wogonin, an active compound extracted from Huang-Qin (Scutellaria baicalensis 
Georgi), has been reported to have anti-oxidant, anti-viral, anti-inflammatory and 
anti-thrombotic activities (Chang et al., 2001; Li-Weber, 2009; Li-Weber, 2010). In 
addition, Wogonin induces apoptosis in various human tumor cells in vitro and 
inhibits tumor growth in vivo in several tumor-bearing mouse models (Li-Weber, 
2010). Our group has reported that Wogonin attenuates NF-κB activity by shifting 
TNFα-induced ·O2– radicals to a more reduced nonradical product, H2O2, and thereby 
sensitizes TNFα-resistant leukemia cells to TNFα-induced apoptosis. In addition, 
Wogonin overcomes TRAIL resistance in primary AML (acute myeloid leukemia) 
cells (Fas et al., 2006). However, the molecular mechanisms need to be further 
investigated.  
In this study, we showed that Wogonin restored TRAIL sensitivity in 
HTLV-1-associated ATL cells and the effect of Wogonin in combination of TRAIL 
was rather synergistic than additive (Fig. 3.2). Importantly, Wogonin does not affect 
the viability of peripheral blood T cells derived from healthy donors. Consistent with 
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our previous finding (Fas et al., 2006), Wogonin does not sensitize TRAIL-induced 
apoptosis in non-malignant T cells (Fig. 3.4). Moreover, it has been reported that 
Wogonin offers a wide margin of safety and had no organ toxicity following long term 
intravenous administration in dogs (Peng et al., 2009). Thus, Wogonin is a promising 
agent to overcome TRAIL resistance.  
 
4.2 Mechanisms of Wogonin-mediated sensitization of 
TRAIL-induced apoptosis 
4.2.1 Wogonin suppresses expression of c-FLIP  
Elevated c-FLIP expression can confer resistance to TRAIL-induced apoptosis in 
various tumor cells (Roth and Reed, 2004; Shirley and Micheau, 2010). Previously, 
our group has shown that high expression of c-FLIP protein in HTLV-1-associated 
ATL cells suppresses CD95-mediated apoptosis (Krueger et al., 2006). c-FLIP 
knockdown in cells which express abnormal high c-FLIP levels restores sensitivity to 
CD95 or TRAIL-mediated apoptosis (Krueger et al., 2006; Okamoto et al., 2006; 
Bleumink et al., 2010). In this study, c-FLIP protein expression is inhibited by 
Wogonin (Fig. 3.5), suggesting that the suppression of c-FLIP expression is one 
possible mechanism by which Wogonin recovers TRAIL sensitivity in 
HTLV-1-associated ATL cells. 
c-FLIP mRNA expression in ATL cells is elevated compared to Jurkat 16 cells (Fig. 
3.6) and can be rapidly reduced by Wogonin treatment (Fig. 3.7). This reveals that 
Wogonin is modulating c-FLIP expression on the level of mRNA. Recently, our 
group has demonstrated that Wogonin is a potent inhibitor of CDK9 which plays a 
major role in regulation of transcription. The expression of proteins is suppressed at 
the transcriptional level by Wogonin treatment (Polier et al., unpublished data). It has 
been reported that the mRNA of c-FLIP isoforms have a short half-life of about 2 
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hours (Fulda et al., 2000; Hernandez et al., 2001). This is possibly the mechanism by 
which Wogonin inhibits c-FLIP mRNA expression at the early time periods. 
c-FLIP is reported to be a transcriptional target of NF-κB (Shirley and Micheau; 
2010). The Tax protein plays a role in NF-κB activation by constitutively activating 
IKK through physical interaction with it (Sun and Yamaoka, 2005; Mori et al., 2001; 
Tsukahara et al., 1999). Therefore, the effects of Wogonin on Tax expression were 
analyzed to investigate whether Wogonin inhibits c-FLIP expression by suppression 
of Tax. However, we found that Wogonin does not inhibit Tax expression (Fig. 3.27). 
Thus, down-regulation of c-FLIP expression by Wogonin is not through inhibition of 
Tax.  
Our group has shown previously that Wogonin attenuates NF-κB activity by shifting 
TNFα-induced free radical ·O2– to a more reduced nonradical product, H2O2, and 
thereby sensitizes TNFα-resistant leukemic cells to TNFα-induced apoptosis (Fas et 
al., 2006). Several other publications also reported that Wogonin suppresses NF-κB 
activity by inhibiting the NF-κB nuclear translocation and IκB phosphorylation (Zhao 
et al., 2010; Piao et al., 2008; Li-Weber, 2010). Therefore, inhibition of NF-κB 
activity by Wogonin may contribute to the down-regulation of c-FLIP expression and 
the recovery of TRAIL sensitivity. 
c-FLIP is widely accepted as an anti-apoptotic protein by preventing further 
recruitment and processing of pro-caspase-8 at the DISC (Shirley and Micheau; 2010). 
However, it was also reported that c-FLIPL has pro-apoptotic effects (Lamkanfi et al., 
2007; Yu and Shi, 2008) and it can function as a pro-apoptotic molecule at low 
expression, promoting the activation of pro-caspase-8 at the DISC (Chang et al., 
2002). c-FLIPL expression was decreased after 3 h of Wogonin treatment and 
dramatically inhibited after 24 h in ATL cells (Fig. 3.5B). These results suggest that 
Wogonin may down-regulate c-FLIPL expression to a low level as a pro-apoptotic 
protein to sensitize towards TRAIL-induced apoptosis. More recently, our laboratory 
has defined the exact quantities of c-FLIPL which lead to pro-apoptotic effects. 
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c-FLIPL has a pro-apoptotic role only at moderate expression of c-FLIPL with strong 
receptor stimulation or with high amounts of c-FLIPS or c-FLIPR (Fricker et al., 2010). 
As seen in Fig.3.16, c-FLIPL, c-FLIPS and c-FLIPR are all aberrantly elevated in ATL 
cells compared to Jurkat 16 cells. According to the finding of Fricker and his 
colleagues, high c-FLIP isoform expression levels in ATL cells do not fit the condition 
for c-FLIPL acting as a pro-apoptotic protein. In this case, c-FLIPL functions as an 
anti-apoptotic protein and down-regulation of it by Wogonin contributes to TRAIL 
sensitization. 
Taken together, down-regulation of c-FLIP expression by Wogonin is one of the 
mechanisms to overcome TRAIL resistance in HTLV-1-associated ATL cells. The 
inhibition of c-FLIP expression at the transcriptional level is possibly due to CDK9 
suppression and/or NF-κB inactivation by Wogonin treatment. 
 
4.2.2 Wogonin up-regulates TRAIL-R2 expression 
Aberrant expression of TRAIL receptors can result in tumor cell resistance to 
TRAIL-induced apoptosis. Low or no expression of TRAIL death receptors, or 
increased expression of TRAIL decoy receptors, may temper TRAIL-induced cell 
death (Fisher et al., 2001; McDonald et al., 2001; Mérino et al. 2007). Up-regulation 
of TRAIL death receptor expression by several agents has been reported as a 
mechanism to overcome TRAIL resistance (Shankar et al., 2004; Debatin and 
Krammer, 2004). In this study, we found that Wogonin enhances TRAIL-R2 protein 
and surface expression without influencing the expression of the other TRAIL 
receptors (Fig. 3.8 and Fig. 3.9). Although surface expression of TRAIL death 
receptors in HTLV-1-associated ATL cells are comparable with those in control CEM 
and Jurkat cells (Bleumink et al., 2010), the increased expression of TRAIL death 
receptors may still be a mechanism of sensitizing tumor cells to TRAIL-induced 
 
 
Discussion                
 103
apoptosis. 
Studying the mechanism by which Wogonin up-regulates TRAIL-R2 expression 
revealed that Wogonin suppressed TRAIL-R2 mRNA expression level at early time 
points (0-6 h) but increased its mRNA expression after 6 h of treatment (Fig. 3.10). 
Since TRAIL-R2 transcripts have a half-life of about 4 h (Kandasamy et al., 2008), 
this is consistent with our finding that Wogonin suppressed TRAIL-R2 mRNA 
expression after 0-6 h of treatment. Additionally, the observation that TRAIL mRNA 
expression was increased by Wogonin at later time points (9 to 24 h) could be 
explained by up-regulation of p53 (Fig. 3.10 and Fig. 3.11). Three p53 DNA-binding 
sites have been identified in the TRAIL-R2 genomic locus located upstream (-0.82 Kb) 
of the ATG site, within Intron 1 (+0.25 Kb downstream of the ATG) and within Intron 
2 (+1.25 Kb downstream of the ATG). p53 transactivates the TRAIL-R2 gene through 
the intronic sequence-specific DNA-binding site (+ 0.25 Kb downstream of the ATG) 
(Takimoto et al., 2000). Therefore, up-regulation of p53 by Wogonin could increase 
TRAIL-R2 expression in HTLV-1-associated ATL cell lines. Several agents, such as 
the natural compound triptolide and MDM2 inhibitor nutlin-3 have also been shown 
to sensitize AML or human melanoma cells to TRAIL-induced apoptosis via a 
p53-mediated increase of TRAIL-R2 (Carter et al., 2008; Tseng et al., 2010).  
The mechanism by which Wogonin increases p53 protein expression was further 
analyzed. p53 protein expression is strictly controlled by its negative regulator MDM2 
which targets p53 for ubiquitination and subsequently degradation by the 26S 
proteasome (Manfredi, 2010). We showed that Wogonin rapidly suppressed MDM2 
protein expression, which explains the increased p53 protein levels after Wogonin 
treatment (Fig. 3.11 and Fig. 3.12). In addition, Wogonin can suppress CDK9 activity 
and thus inhibits gene transcription (Polier et al., unpublished data). p53 mRNA 
half-life is about 4 to 6 h (Mazan-Mamczarz et al., 2003; Zhao et al., 2008) and 
MDM2 mRNA is about 20 to 40 min (Wang et al., 2002; Itahana et al., 2007). 
Therefore, this explains that MDM2 is down-regulated faster than p53 at the 
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transcriptional level upon Wogonin treatment (Fig. 3.13). 
It has been reported that MDM2 can act as an oncogene through p53-independent 
activities which regulate proliferation, apoptosis and epithelial-to-mesenchymal 
transitions. As an example, overexpression of MDM2 caused mammary epithelial 
cells to undergo multiple rounds of S phase without cell division both in p53 wild type 
and p53 knockout mice, suggesting that MDM2 regulation of cell cycle progression is 
independent of p53 (Lundgren et al., 1997). Additionally, MDM2 has been shown to 
prevent apoptosis by physically binding to the mRNA that encodes XIAP and 
enhancing its expression (Gu et al., 2009). Most notably, MDM2 has been reported to 
modify E-cadherin for degradation via the 26S proteasome, which leads to an 
epithelial-to-mesenchymal transition, a vital step of metastasis in solid tumors of 
epithelial origin (Yang et al., 2006; Thiery et al., 2009). In this study, Wogonin 
suppresses MDM2 expression suggesting that even in p53 mutated tumors Wogonin 
may still play an anti-cancer role by reducing the expression of the oncogene MDM2. 
Except for p53, CHOP and Sp1 have also been reported to be transcriptional 
regulators of TRAIL-R2 (Yoshida et al., 2001). Several articles have shown that 
certain drugs, such as roscovitine and beta-Ionone, sensitize cancer cells to 
TRAIL-mediated apoptosis through CHOP or Sp1-mediated up-regulation of 
TRAIL-R2 (Kim et al., 2004; Shiraishi et al., 2005; Yoshida et al., 2005; Kim et al., 
2010). However, Wogonin influences neither CHOP nor Sp1 protein expression in SP 
and MT-4 cells (Fig. 3.15). Thus, in HTLV-1-associated ATL cells up-regulation of 
TRAIL-R2 by Wogonin is unlikely to be mediated through the transcription factors 
CHOP and Sp1.  
Recently, one publication has reported that Wogonin enhances TRAIL-induced 
apoptosis through the up-regulation of p53 and Puma, mediated by DNA damage and 
ROS, in the human prostate cancer cell line LNCaP which is resistant to TRAIL (Lee 
et al., 2009). However, Puma elevation upon Wogonin treatment was not observed in 
HTLV-1-associated ATL cells and CEM cells (Fig. 3.18; Polier et al., unpublished 
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data). In addition, our group found that Wogonin-mediated apoptosis can not be 
blocked by the ROS scavenger NAC in various cancer cell lines (Fas et al., 2006; data 
not shown). Moreover, Wogonin and flavones are compounds with anti-oxidant 
activities (Li-Weber, 2009; Li-Weber, 2010). Therefore, it is unlikely that ROS play a 
role in Wogonin-mediated sensitization of TRAIL-induced apoptosis in 
HTLV-1-associated ATL cells. 
In this study, Wogonin up-regulates TRAIL-R2 via elevated p53 expression in 
HTLV-1-associated ATL cell lines. p53 is wild type in sequence in most of 
HTLV-1-associated ATL cell lines, including the ones used in this study. However, it 
has been reported that p53 function is inhibited by the Tax-mediated NF-κB 
activation in ATL cell lines (Pise-Masison et al., 2000; Jeong et al., 2004). Since 
Wogonin can inhibit NF-κB activity by shifting the free radical ·O2– to a more reduced 
nonradical product, H2O2, or by inhibiting the NF-κB nuclear translocation and IκB 
phosphorylation (Fas et al., 2006; Zhao et al., 2010; Piao et al., 2008; Li-Weber, 
2010), this suggested that suppression of NF-κB activity by Wogonin may contribute 
to the enhanced expression of p53 in HTLV-1-associated ATL cell cells. However, it 
has to be further investigated whether Wogonin can increase the activity of p53.  
p53 status in ATL patients has been studied by several groups. They have shown that 
p53 is often mutated in patients with acute ATL rather than in patients with chronic 
ATL. In addition, it was suggested that p53 mutations may be involved in the 
transition from the chronic to the acute stage of ATL (Nagai et al., 1991; Sakashita et 
al., 1992; Yamato et al., 1993; Tabakin-Fix et al., 2006). These reports imply that for 
the best therapeutic effect, Wogonin treatment should be performed in ATL patients 
as early as possible at the chronic stage.  
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4.2.3 Effect of Wogonin on the expression of pro- and anti-apoptotic 
proteins 
     In this study, we demonstrate that Wogonin overcomes TRAIL resistance in 
HTLV-1-associated ATL cells via suppression of c-FLIP expression and enhancement 
of TRAIL-R2 expression. It has been reported that impaired expression of 
pro-apoptotic proteins, such as Bax (LeBlanc et al., 2002), or over-expression of 
anti-apoptotic proteins, e.g., XIAP (Hersey et al., 2003), Mc-1 (Kim et al., 2008) and 
Bcl-2 (Fulda et al., 2002) may also confer resistance to TRAIL in cancer cells. 
Therefore, expression of pro- and anti-apoptotic proteins in the intrinsic apoptosis 
pathways were compared in HTLV-1-associated ATL cells and control Jurkat 16 cells. 
This analysis showed that consistent with other studies (Krueger et al., 2006; 
Bleumink et al., 2010) that the anti-apoptotic proteins, Bcl-xL, Bcl-2 and Mcl-1 are 
increased in HTLV-1-associated ATL cell lines. However, the pro-apoptotic proteins 
Bad and Bax are also elevated when compared to Jurkat 16 cells (Fig. 3.16). It has 
been reported that the fate of a cell is largely determined by the amounts of pro- and 
anti-apoptotic proteins of the Bcl-2 family (Fletcher and Huang, 2008). Since the 
expression of both anti- and pro-apoptotic proteins is elevated in HTLV-1-associated 
ATL cells, it is hard to conclude whether these proteins play a role in TRAIL 
resistance in ATL cells.  
In addition, treatment of Wogonin in HTLV-1-associated ATL cells inhibits Mcl-1 
expression (Fig. 3.18), which explains that Wogonin alone can induce about 10 % to 
20 % of cell death (Fig. 3.2). We also found that Wogonin inhibits Mcl-1 expression at 
the transcriptional level (Fig. 3.19). Since Wogonin suppresses CDK9 activity and 
blocks gene transcription elongation (Polier et al., unpublished data) and Mcl-1 has a 
short mRNA half life of about 2 h (Derouet et al., 2006; Akgul, 2009), this explains 
that Wogonin inhibits Mcl-1 transcription at early time periods.  
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4.3 Apigenin and Chrysin overcome TRAIL resistance 
Wogonin, Apigenin and Chrysin belong to the chemical class of flavones and share a 
common chemical structure, consisting of fused A and C rings, and a phenyl B ring 
attached to position 2 of the C ring (Fig. 1.5). Both Apigenin and Chrysin are reported 
to have anti-inflammatory, anti-viral, anti-oxidant and anti-cancer activities (Shukla et 
al., 2007; Li-Weber, 2010; Khoo et al., 2010). Additionally, Apigenin has also been 
shown to inhibit tumor invasion and metastasis by suppressing the expression of 
HIF-1α and VEGF in human ovarian cancer cells (Fang et al., 2005) and by inhibiting 
intracellular adhesion molecule 1 (ICAM1) in human endothelial cells (Panés et al., 
1996).  
Our group has recently shown that these compounds inhibit CDK9 activity and thus 
suppress transcription elongation (Polier et al., unpublished data). In this study, 
Apigenin and Chrysin act similar to Wogonin to sensitize HTLV-1-associated ATL 
cells to TRAIL-induced apoptosis. Apigenin and Chrysin both down-regulate c-FLIP 
expression at the transcriptional level and increase TRAIL-R2 via up-regulation of 
p53 through inhibition of the p53 negative regulator MDM2 (Fig. 3.22 - Fig. 3.25). 
Additionally, suppression of TRAIL-R3 was observed in MT-2 cells after treatment 
with Apigenin and Chrysin (Fig. 3.23). It has been reported that decoy receptors may 
compete with death receptors for TRAIL binding (Pan et al., 1997; Degli-Esposti MA 
et al., 1997a; Degli-Esposti MA et al., 1997b; Mérino et al. 2007). Ectopic 
over-expression of decoy receptors in TRAIL-sensitive cells leads to TRAIL 
resistance (Mérino et al., 2006; Marsters et al., 1997). Similarly, TRAIL sensitivity 
could be restored in resistant cells by using anti-DcRs blocking antibodies or siRNA 
to decrease DcR expression (Sanlioglu et al., 2005; Sanlioglu et al., 2007). Therefore, 
inhibition of TRAIL-R3 expression might be another mechanism by which Apigenin 
and Chrysin overcome TRAIL resistance. It needs to be further investigated whether 
this is the case in HTLV-1-associated ATL cells. 
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4.4 Schematic representation of the mechanism by which 
Wogonin, Apigenin and Chrysin sensitize TRAIL-induced 
apoptosis 
In summary, our group found previously that Wogonin, Apigenin and Chrysin inhibit 
CDK9 activity and suppress gene expression at the transcriptional level (Polier et al., 
unpublished data). In this study we show that Wogonin, Apigenin and Chrysin can 
sensitize TRAIL-mediated apoptosis by down-regulating c-FLIP expression at the 
transcriptional level and by increasing TRAIL-R2 expression via up-regulation of p53 
through inhibition of the p53 negative regulator MDM2 at the transcriptional level 
(Fig. 4.1). Thus, this study raises the possibility to develop Wogonin, Apigenin and 
Chrysin as TRAIL adjuvant for treatment of ATL and other types of tumors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic representation of the mechanism by which Wogonin, Apigenin and 
Chrysin sensitize TRAIL-induced apoptosis 
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ABBREVIATIONS 
Ab – antibody 
AIF – apoptosis inducing factor 
AIDS – acquired immune deficiency syndrome 
AML – acute myeloid leukemia 
AP-1 – activating protein 1 
APS – ammonium persulphate 
Apaf-1 – apoptosis activating factor-1 
ATL – adult T-cell leukemia/lymphoma 
Bcl-2 – B-cell lymphoma-2 
BH3 – Bcl-2 homolgy 3 domain 
BIR – baculoviral IAP repeat 
bp – base pair 
caspase – cysteine aspartate-specific protease 
CD – (CD4 / CD95) - cluster of differentiation 
CD95L – CD95 ligand 
CDK – cyclin-dependent kinase 
c-FLIP – cellular FLICE inhibitory protein  
CTL – cytotoxic T cell  
Cyt c – cytochrome c 
DcR – decoy receptor 
DD – death domain 
DED – death-effector domain 
DISC – death-inducing signaling complex 
DMEM – Dulbecco’smodified Eagles Medium 
DMSO – dimethyl sulphoxide 
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DR – death receptor 
DTT – dithiothreitol 
ECL – enhanced chemiluminescense 
EGR1 – early growth response 1 
EDTA – ethylene-diamine-tetra-actetate 
ERK – extracellular signal-regulated kinase 
FACS – fluorescence-activated cell sorter 
FADD – Fas-associated death domain protein 
FBS – fetal bovine serum 
FITC – fluorescein isothiocyanate 
FL – fluorescence 
FLIP (FLIPS / FLIPL) – FADD-like interleukin-1β-converting enzyme-like protease 
[FLICE/caspase-8] - inhibitory protein (short form / long form) 
GLUT1 – glucose transporter 1 
GRP – guanyl nucleotide-releasing protein 
HAM – HTLV associated myelopathy 
HDAC – histone deacetylases  
h – hour 
HRP – horseradish peroxidase 
HSPGs – heparin sulfate proteoglycans  
HTLV – human T-cell leukemia/lymphoma virus 
IAP – inhibitor of apoptosis 
Ig – immunoglobulin 
IκB – inhibitor of NF-κB 
IKK – IκB kinase 
kD – kilo Dalton 
LTR – long terminal repeat 
MAPK (MAP kinase) – mitogen-activated protein kinase 
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Mcl-1 – myeloid cell leukemia sequence 1 
MDM2 – mouse double minute 2 
mTOR – mammalian target of rpamycin  
NFAT – nuclear factor of activated T cells 
NF-κB – nuclear factor – κB  
NK – natural killer 
NRP1 – neuropilin 1  
ORF – overlapping reading frame  
PAGE – polyacrylamide gel electrophoresis 
PBS – phosphate buffer saline 
PCR – polymerase chain reaction 
PFA – paraformaldehyde 
PI – propidium iodide 
PI3K – phosphoinositide 3 kinase 
PMSF – phenyl-methanesulphonylfluoride 
RIPA (lysis buffer) – radioimmunoprecipitation (lysis buffer) 
ROS – reactive oxygen species 
rpm – rotations per minute 
RPMI medium – Roswell Park Memorial Institute medium 
RRE – Rex response element  
RT– reverse transcriptase 
RT – room temperature 
SDS – sodium dodecyl sulfate 
Smac/DIABLO – second mitochondria-derived activator of caspase/directed IAP 
binding protein with low pI 
TBE – Tris-Borate-EDTA 
TEMED – N,N,N’,N’ – tetramethyl-ethylenediamine 
TM – transmembrane domain  
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TNF – tumor necrosis factor 
TRE – triplicate enhancer element 
TSP – tropical spastic paraparesis 
TRAF – tumor necrosis factor receptor-associated factor 
TRAIL – TNF-α-related apoptosis-inducing ligand 
TRAIL-R – TRAIL receptor 
Tris – Tris-[hydroxymethyl]amino-methane 
U – unit 
UV – ultraviolet 
XIAP – X-linked Inhibition of Apoptosis Protein 
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